Genetic regulation of immune responses through chromosomal interactions

By detecting chromosomal interactions, the problem of difficult to predict patients' immune response in the prior art is solved, accurate monitoring of immune responses and personalized treatment plans are achieved, and the treatment effect is improved.

CN111511930BInactive Publication Date: 2024-11-22OXFORD BIODYNAMICS PLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201880083380.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-10-03
Filing Date
2018-11-02
Publication Date
2024-11-22
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art is difficult to effectively predict the patient's response to a specific therapy, especially during the disease process, and it is difficult to determine the patient's immune response status, resulting in poor treatment results.

Method used

By detecting the chromosomal states representing subgroups in the population, the EpiSwitchTM system is used to identify chromosomal interactions related to the immune response, determine the presence or absence of specific chromosomal interactions, and then determine the patient's immune response status, providing personalized treatment plans.

Benefits of technology

Accurate monitoring and prediction of patients' immune responses is achieved, personalized treatment plans are provided, treatment effects are improved, and disease progression can be intervened in early stages.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0002552191860000361
    Figure BDA0002552191860000361
  • Figure BDA0002552191860000371
    Figure BDA0002552191860000371
  • Figure BDA0002552191860000372
    Figure BDA0002552191860000372
Patent Text Reader

Abstract

A method for analyzing chromosomal regions and interactions associated with immune responses.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to detecting chromosome interactions. Background Art

[0002] The disease process is complex and the outcome cannot be predicted using the available methods. In particular, it is difficult to predict how a patient will respond to a specific therapy. Summary of the invention

[0003] Specific chromosome conformation signatures (CCS) at a locus are present or absent due to regulatory epigenetic control settings associated with pathology or treatment. CCSs have a mild off-rate and when representing a specific phenotype or pathology, they will only change as a result of physiological signaling to a new phenotype or due to external intervention. Furthermore, the measurements of these events are binary, so this readout is in stark contrast to the continuous readouts of varying levels of DNA methylation, histone modifications, and most non-coding RNAs. To date, the continuous readouts used by most molecular biomarkers present challenges for data analysis because the magnitude of change in a particular biomarker varies greatly from patient to patient, which creates problems for categorical statistics when using them to stratify patient populations. These categorical statistics are more appropriate for using biomarkers that do not have a magnitude and only provide a binary score of a “yes or no” phenotypic difference, indicating that chromosome conformation (EpiSwitch TM ) biomarkers are an excellent resource of potential diagnostic, prognostic, and predictive biomarkers.

[0004] The inventors have identified genomic regions with chromosomal interactions related to immune response (immunoresponsiveness) using methods that allow identification of subgroups in a population. Identification regions, genes and specific chromosomal interactions from two independent studies using different therapies to treat two different conditions have been found to determine the general immune response of the patient, including regulation of cell surface signaling pathways and regulation of T cell activation by the immune response. The inventors' work allows tracking changes in immune response, such as during disease or treatment.

[0005] Thus, the present invention provides a method for detecting the chromosome state of a subgroup representative of a population, comprising determining the presence or absence of chromosome interactions associated with the chromosome state within a defined region of the genome, wherein the subgroup is associated with the state of an immunoresponsive individual; and

[0006] - wherein the chromosomal interactions are optionally identified by a method for determining which chromosomal interactions are associated with chromosomal states corresponding to immune response subsets of a population, the method comprising contacting a first set of nucleic acids from subsets having different chromosomal states with a second set of index nucleic acids, and allowing complementary sequences to hybridize, wherein nucleic acids in the first and second sets of nucleic acids represent ligation products comprising sequences from two chromosomal regions that are brought together in the chromosomal interaction, and wherein the hybridization pattern between the first and second sets of nucleic acids allows for determination of which chromosomal interactions are specific to the immune response subsets; and

[0007] - where chromosomes interact:

[0008] (i) present in any of the regions or genes listed in Table 1; and / or

[0009] (ii) corresponds to any of the chromosomal interactions represented by any of the probes shown in Table 1, and / or

[0010] (iii) is present in a region comprising or flanking 4,000 bases of (i) or (ii).

[0011] The present invention also provides a method for detecting the chromosome state of a subgroup representing a population, comprising determining the presence or absence of a chromosome interaction associated with the chromosome state within a defined region of the genome, wherein the subgroup is associated with the state of an immune responsive individual; and

[0012] - wherein the chromosomal interactions are optionally identified by a method for determining which chromosomal interactions are associated with chromosomal states corresponding to immune response subsets of a population, the method comprising contacting a first set of nucleic acids from subsets having different chromosomal states with a second set of index nucleic acids, and allowing complementary sequences to hybridize, wherein nucleic acids in the first and second sets of nucleic acids represent ligation products comprising sequences from two chromosomal regions that are brought together in the chromosomal interaction, and wherein the hybridization pattern between the first and second sets of nucleic acids allows for determination of which chromosomal interactions are specific to the immune response subset; and

[0013] - where chromosomes interact:

[0014] a) present in any of the regions or genes listed in Table 13; and / or

[0015] b) corresponds to any of the chromosome interactions represented by any of the probes shown in Table 13, and / or

[0016] c) is present in a region of 4,000 bases that includes or flanks (a) or (b).

[0017] The present invention further provides a method for detecting the chromosome state of a subgroup representative of a population, comprising determining the presence or absence of a chromosome interaction associated with the chromosome state within a defined region of the genome, wherein the subgroup is associated with the state of an immune responsive individual; and

[0018] - wherein the chromosomal interactions are optionally identified by a method for determining which chromosomal interactions are associated with chromosomal states corresponding to immune response subsets of a population, comprising contacting a first set of nucleic acids from subsets having different chromosomal states with a second set of index nucleic acids, and allowing complementary sequences to hybridize, wherein the nucleic acids in the first and second sets of nucleic acids represent ligation products comprising sequences from two chromosomal regions that are brought together in the chromosomal interaction, and wherein the hybridization pattern between the first and second sets of nucleic acids allows for determination of which chromosomal interactions are specific to the immune response subset; and

[0019] - where chromosomes interact:

[0020] (α) present in any of the regions or genes listed in Table 16; and / or

[0021] (β) corresponds to any of the chromosome interactions represented by any of the probes shown in Table 16, and / or

[0022] (γ) is present in a 4,000 base region that includes or flanks (α) or (β). DETAILED DESCRIPTION

[0023] Aspects of the Invention

[0024] The present invention relates to a panel of epigenetic markers involved in the regulation of the immune system, in particular through cell surface signaling pathways and T cell activation.

[0025] The present invention also includes monitoring the state of the immune system to determine its responsiveness to a particular therapy. This means that the appropriate therapy can be provided to the patient and it can be determined whether the patient has retained or lost the 'responder' state. Thus, in one embodiment, the present invention provides a 'real time' continuous readout of the 'responder' state, allowing the treatment of the patient to be personalized to accurately reflect the patient's needs.

[0026] Immune responsiveness

[0027] The present invention relates to determining immunoresponsiveness. This is preferably the responsiveness to a therapy comprising a molecule or cell related to the immune system, such as administering a composition comprising an antibody or an immune cell (such as a T cell or a dendritic cell) or administering any therapeutic substance mentioned herein. It can be the responsiveness to a substance that regulates or stimulates the immune system, such as a vaccine therapy. Therefore, immunoresponsiveness is preferably the responsiveness to immunotherapy. Immunotherapy can regulate, block or stimulate immune checkpoints, so PD-L1, PD-L2 or CTLA4 or any other immune checkpoint molecules disclosed herein can be targeted or regulated, and therefore can be immune checkpoint therapy. Preferably, immunoresponsiveness is the responsiveness to antibody therapy or any specific therapy disclosed herein (see specific drugs in the later article section). The therapy can be a combination therapy.

[0028] In one embodiment, the immune responsiveness is responsiveness to a PD-1 inhibitor or a PD-L1 inhibitor, including responsiveness to antibodies specific for PD-1 or PD-L1. PD-1 is 'programmed cell death protein' and PD-L1 is 'programmed death ligand 1'.

[0029] Immune responsiveness is preferably directed to a cancer therapy, and is therefore generally related to whether a particular individual responds to that therapy, wherein the individual may or may not have cancer, or may be at risk of having cancer. Cancer is generally any cancer mentioned herein, and is for example melanoma, lung cancer, non-small cell lung cancer (NSCLC), diffuse large B-cell lymphoma, liver cancer, hepatocellular carcinoma, prostate cancer, breast cancer, leukemia, acute myeloid leukemia, pancreatic cancer, thyroid cancer, nasal cancer, brain cancer, bladder cancer, cervical cancer, non-Hodgkin's lymphoma, ovarian cancer, colorectal cancer or kidney cancer.

[0030] The term 'antibody' includes all fragments and derivatives of antibodies that retain the ability to bind to the antigen target, such as single chain scFV or Fab.

[0031] As will be discussed later, the immune responsiveness to any therapy, cell or drug mentioned herein can be determined. In some embodiments, any therapy, cell or drug mentioned herein can be administered to an individual in whom the immune response has been determined.

[0032] Method of the present invention

[0033] The method of the present invention includes a typing system for detecting chromosome interactions associated with immune responses. This typing can use the EpiSwitch® based on chromosome cross-linked regions that are clustered together in chromosome interactions. TMThe system is carried out by cleaving the chromosomal DNA and then connecting the nucleic acids present in the cross-linked entities to derive a linked nucleic acid having sequences from the two regions forming the chromosomal interaction. Detection of this linked nucleic acid allows the determination of the presence or absence of a specific chromosomal interaction.

[0034] Chromosomal interactions can be identified using the methods described above, wherein a first and a second nucleic acid population are used. EpiSwitch TM Technology to generate these nucleic acids.

[0035] Epigenetic interactions relevant to the present invention

[0036] As used herein, the terms 'epigenetic' and 'chromosomal' interactions generally refer to interactions between distal regions of chromosomes that are dynamic and are altered, formed or disrupted depending on the state of the chromosomal regions.

[0037] In a particular method of the invention, chromosome interactions are typically detected by first generating linked nucleic acids comprising sequences from two regions of a chromosome that are part of the interaction. In such a process, the regions can be cross-linked by any suitable means. In a preferred embodiment, the interactions are cross-linked using formaldehyde, but can also be cross-linked by any aldehyde or D-biotin-e-aminocaproic acid-N-hydroxysuccinimide ester or digoxigenin-3-O-methylcarbonyl-e-aminocaproic acid-N-hydroxysuccinimide ester. Paraformaldehyde can cross-link DNA strands that are 4 angstroms apart. Preferably, the chromosome interactions are on the same chromosome and are optionally 2 to 10 angstroms apart.

[0038] Chromosomal interactions can reflect the state of a chromosomal region, for example, whether it is transcribed or repressed in response to changes in physiological conditions. Chromosomal interactions defined herein that are specific to subgroups have been found to be stable, thus providing a reliable method to measure differences between two subgroups.

[0039] In addition, for example, compared with other epigenetic markers (such as methylation or histone binding changes), the chromosome interaction specific to a certain feature (such as immunoresponsiveness) will usually occur in the early stage of biological processes. Therefore, the method of the present invention can detect the early stage of biological processes. This allows early intervention (such as treatment), thereby possibly more effective. The chromosome interaction also reflects the current state of the individual, and is therefore useful for assessing the change of immune response. In addition, the related chromosome interaction between individuals in the same subgroup is almost unchanged. Detecting chromosome interaction is very useful, and each gene has 50 possible interactions at most, so the method of the present invention can query 500,000 different interactions.

[0040] Preferred marker panel

[0041] In this article, the term 'marker' or 'biomarker' refers to a specific chromosome interaction that can be detected (typed) in the present invention. Specific markers are disclosed herein, and any of them can be used in the present invention. Additional marker groups can be used, for example, in combinations or numbering disclosed herein. The specific markers disclosed in the table herein are preferred, and the markers present in the genes and regions mentioned in the table herein are preferred. These can be typed by any suitable method, such as PCR-based or probe-based methods disclosed herein, including qPCR methods. Markers are defined herein by position or by probe and / or primer sequences.

[0042] The where and why of epigenetic interactions

[0043] Epigenetic chromosome interactions may overlap and include chromosome regions that are shown as encoding related or undescribed genes, but may also be in intergenic regions. It should also be noted that the inventors have found that in determining the state of chromosome locus (locus, site), epigenetic interactions in all regions are equally important. These interactions are not necessarily in the coding region of the specific gene located at the locus, but may be in the intergenic region.

[0044] The chromosome interactions detected in the present invention may be caused by changes in the underlying DNA sequence, environmental factors, DNA methylation, non-coding antisense RNA transcripts, non-mutagenic carcinogens, histone modifications, chromatin remodeling and specific local DNA interactions. Changes that lead to chromosome interactions may be caused by changes in the underlying nucleic acid sequence, which itself does not directly affect gene products or gene expression patterns. Such changes may be, for example, SNPs inside and / or outside the gene, gene fusions and / or deletions of intergenic DNA, microRNAs and non-coding RNAs. For example, it is known that approximately 20% of SNPs are located in non-coding regions, and therefore, the above method is also useful in non-coding situations. In one embodiment, the regions of chromosomes that are clustered together to form interactions are less than 5kb, 3kb, 1kb, 500 base pairs or 200 base pairs apart on the same chromosome.

[0045] Preferably, the chromosomal interaction detected is within any of the genes mentioned in Table 1. However, it may also be upstream or downstream of said gene, for example up to 50,000, up to 30,000, up to 20,000, up to 10,000 or up to 5000 bases upstream or downstream from said gene or coding sequence.

[0046] Preferably, the detected chromosomal interaction is within any of the genes mentioned in Table 13. However, it may also be upstream or downstream of said gene, for example, up to 50,000, up to 30,000, up to 20,000, up to 10,000 or up to 5000 bases upstream or downstream from said gene or coding sequence.

[0047] Preferably, the detected chromosomal interaction is within any of the genes mentioned in Table 16. However, it may also be upstream or downstream of said gene, for example up to 50,000, up to 30,000, up to 20,000, up to 10,000 or up to 5000 bases upstream or downstream from said gene or coding sequence.

[0048] Subgroups, time points, and personalized treatment

[0049] The object of the present invention is to determine the level of immune response. This can be at one or more defined time points, for example at at least 1, 2, 5, 8 or 10 different time points. The duration between at least 1, 2, 5 or 8 time points can be at least 5, 10, 20, 50, 80 or 100 days. Usually at least 1, 2 or 5 time points are before the treatment starts and / or at least 1, 2 or 5 time points are after the treatment starts.

[0050] As used herein, "subgroup" preferably refers to a subgroup of a population (a subgroup within a population), more preferably a subgroup of a population of a specific animal, such as a specific eukaryotic organism or mammal (e.g., human, non-human, non-human primate, or rodent, such as mouse or rat). Most preferably, "subgroup" refers to a subgroup within the human population.

[0051] The present invention includes specific subgroups in detection and treatment colonies. The inventors have found that chromosome interactions are different between subsets (e.g., at least two subsets) of a given colony. Identifying these differences will enable doctors to classify patients as a part of a subset of the colony described in this method. Therefore, the present invention provides a method for doctors to provide personalized medicine based on patient epigenetic chromosome interactions.

[0052] In one embodiment, the present invention involves testing whether an individual is a 'responder'. Once a person is found to be a 'responder', relevant treatment can be given, which is usually a treatment for an immune checkpoint molecule (such as PD-1, PD-L1 or CTLA4). In one embodiment, if the individual is found to be a non-responder, they will be given a combination therapy, such as any of the combination therapies listed herein. Typically, the combination therapy comprises an antibody and a small molecule.

[0053] Generating ligated nucleic acids

[0054] Certain embodiments of the invention utilize linked nucleic acids, particularly linked DNA. These contain sequences from two regions that come together in a chromosome interaction and thus provide information about the interaction. TM The method uses the generation of such linked nucleic acids to detect chromosome interactions.

[0055] Thus, the methods of the invention may comprise the step of producing a linked nucleic acid (eg, DNA) by the following steps (including a method comprising these steps):

[0056] (i) cross-linking, preferably in vitro, epigenetic chromosomal interactions present at a chromosomal locus;

[0057] (ii) optionally isolating the cross-linked DNA from the chromosomal locus;

[0058] (iii) subjecting the cross-linked DNA to cleavage, such as restriction digestion, by an enzyme that cuts at least once (particularly an enzyme that cuts at least once within the chromosomal locus);

[0059] (iv) ligating the cross-linked sheared DNA ends (particularly forming a DNA loop); and (v) optionally identifying the presence of the ligated DNA and / or the DNA loop, in particular using techniques such as PCR (polymerase chain reaction) to identify the presence of specific chromosomal interactions.

[0060] For any embodiment mentioned herein, these steps can be performed to detect chromosome interactions. The steps can also be performed to generate the first and / or second groups of nucleic acids mentioned herein.

[0061] PCR (polymerase chain reaction) can be used for detecting or identifying the nucleic acid connected, for example the size of the PCR product produced can indicate the specific chromosome interaction present, and therefore can be used for identifying the state of the locus. In a preferred embodiment, at least 1,2 or 3 primers or primer pairs shown in Table 4 are used in the PCR reaction. In other embodiments, at least 1,2 or 3 primers or primer pairs shown in Table 13 are used in the PCR reaction. In other embodiments, the PCR reaction uses at least 1,2 or 3 primers or primer pairs shown in Table 17. Those skilled in the art will understand that many restriction enzymes that can be used for cutting the DNA in the target chromosome locus. Obviously, the specific enzyme used will depend on the locus studied and the sequence of the DNA therein. The non-limiting example of a restriction enzyme that can be used for cutting DNA as described in the present invention is TaqI.

[0062] Such as EpiSwitch TM Technology and other implementation methods

[0063] EpiSwitch TM EpiSwitch TM The marker data detects epigenetic chromosome conformation signatures that are specific to the phenotype. Embodiments utilizing linked nucleic acids in the manner described herein, such as EpiSwitch TM , have several advantages. They have lower levels of random noise, for example because a nucleic acid sequence from the first set of nucleic acids of the invention either hybridizes with or does not hybridize with the second set of nucleic acids. This provides a binary result, allowing complex mechanisms to be measured at the epigenetic level in a relatively simple manner. TM The technology also has fast processing time and low cost. In one embodiment, the processing time is 3 hours to 6 hours.

[0064] Samples and sample processing

[0065] The methods of the invention will typically be performed on a sample. The sample may be obtained at a defined time point, for example at any time point defined herein. The sample typically contains DNA from an individual. It will typically contain cells. In one embodiment, the sample is obtained by minimally invasive means and may be, for example, a blood sample. The DNA may be extracted and cut with standard restriction enzymes. This may predetermine which chromosome conformations are retained and may allow the use of EpiSwitch TM Platform detection. Because chromosome interactions are synchronized between tissue and blood (including horizontal transfer), blood samples can be used to detect chromosome interactions in tissues (e.g., tissues associated with disease). For some conditions, such as cancer, the use of blood is advantageous because genetic noise caused by mutations can affect the chromosome interaction 'signal' in the relevant tissue.

[0066] Properties of the Nucleic Acids of the Invention

[0067] The present invention relates to certain nucleic acids, such as nucleic acids connected as described herein for use or generation in the methods of the present invention. These may be identical to the first and second nucleic acids mentioned herein or have any of their properties. The nucleic acids of the present invention generally comprise two parts, each of which comprises a sequence from one of the two regions of a chromosome that are brought together in a chromosome interaction. Typically, each part has a length of at least 8, 10, 15, 20, 30 or 40 nucleotides, such as a length of 10 to 40 nucleotides. Preferred nucleic acids comprise sequences from any gene mentioned in any table. Typically, preferred nucleic acids comprise the specific probe sequences mentioned in Table 1; or fragments and / or homologues of such sequences. Preferred nucleic acids may comprise the specific probe sequences mentioned in Table 13; or fragments and / or homologues of such sequences. Preferred nucleic acids may comprise the specific probe sequences mentioned in Table 16; or fragments and / or homologues of such sequences.

[0068] Preferably, the nucleic acid is DNA. It should be understood that, in the case of providing a specific sequence, the present invention can use the complementary sequence required in a specific embodiment. Preferably, the nucleic acid is DNA. It should be understood that, in the case of providing a specific sequence, the present invention can use the complementary sequence required in a specific embodiment.

[0069] The primers shown in Table 4 can also be used in the invention described herein. In one embodiment, the primers used include any one of the following: a sequence shown in Table 4; or a fragment and / or homolog of any sequence shown in Table 4. The primers shown in Table 13 can also be used in the invention described herein. In one embodiment, the primers used include any one of the following: a sequence shown in Table 13; or a fragment and / or homolog of any sequence shown in Table 13. The primers shown in Table 17 can also be used in the invention described herein. In one embodiment, the primers used include any one of the following: a sequence shown in Table 17; or a fragment and / or homolog of any sequence shown in Table 17.

[0070] Second set of nucleic acid - 'index' sequences

[0071] The second set of nucleic acid sequences functions as a set of index sequences and is essentially a set of nucleic acid sequences suitable for identifying subgroup specific sequences. They may represent 'background' chromosome interactions and may or may not be selected in some way. They are typically a subset of all possible chromosome interactions.

[0072] The second group of nucleic acids can be obtained by any suitable method. They can be calculated, or can be based on the chromosome interaction in an individual. They generally represent a larger colony than the first group of nucleic acids. In a specific embodiment, the second group of nucleic acids represents all possible epigenetic chromosome interactions in a specific genome. In another specific embodiment, the second group of nucleic acids represents a large part of all possible epigenetic chromosome interactions present in the colony described herein. In a specific embodiment, the second group of nucleic acids represents at least 20, 50, 100 or 500 genes, for example at least 50% or at least 80% of the epigenetic chromosome interactions in 20 to 100 or 50 to 500 genes.

[0073] The second group of nucleic acids generally represents at least 100 possible epigenetic chromosome interactions, which modify, regulate or mediate the phenotype in the colony in any way. The second group of nucleic acids can represent the chromosome interactions that affect the disease state (generally relevant to diagnosis or prognosis) in the species. The second group of nucleic acids generally comprises sequences representing epigenetic interactions that are relevant and unrelated to the immune response subgroup.

[0074] In a specific embodiment, the second group of nucleic acids is at least partially derived from naturally occurring sequences in the population, and is typically obtained by computer methods. The nucleic acid may further comprise single or multiple mutations compared to the corresponding portion of the nucleic acid present in the naturally occurring nucleic acid. The mutation comprises the deletion, substitution and / or addition of one or more nucleotide base pairs. In a specific embodiment, the second group of nucleic acids may comprise sequences representing homologues and / or orthologues having at least 70% sequence identity to the corresponding portion of the nucleic acid present in the naturally occurring species. In another specific embodiment, at least 80% sequence identity or at least 90% sequence identity to the corresponding portion of the nucleic acid present in the naturally occurring species is provided.

[0075] Properties of the second group of nucleic acids

[0076] In a particular embodiment, there are at least 100 different nucleic acid sequences in the second set of nucleic acids, preferably at least 1000, 2000 or 5000 different nucleic acid sequences, with up to 100,000, 1,000,000 or 10,000,000 different nucleic acid sequences. A typical number may be 100 to 1,000,000, such as 1,000 to 100,000 different nucleic acid sequences. All or at least 90% or at least 50% or these will correspond to different chromosome interactions.

[0077] In a specific embodiment, the second group of nucleic acid represents at least 20 different loci or genes, preferably at least 40 different loci or genes, more preferably at least 100, at least 500, at least 1000 or at least 5000 different loci or genes, for example, 100 to 10,000 different loci or gene chromosome interactions. The length of the second group of nucleic acid is suitable for using them to carry out specific hybridization with the first group of nucleic acid according to Watson-Crick (Watson Crick) base pairing, to identify the chromosome interaction specific to the subgroup. Usually, the second group of nucleic acid will comprise two parts, which correspond to two chromosome regions gathered together in the chromosome interaction in sequence. The second group of nucleic acid generally comprises a length of at least 10, preferably 20, and also preferably a nucleic acid sequence of 30 bases (nucleotides). In another embodiment, the length of the nucleic acid sequence can be up to 500, preferably up to 100, and also preferably up to 50 base pairs. In a preferred embodiment, the second group of nucleic acid comprises a nucleic acid sequence of 17 to 25 base pairs. In one embodiment, at least 100, 80% or 50% of the second set of nucleic acid sequences have a length as described above. Preferably, the different nucleic acids do not have any overlapping sequences, for example at least 100%, 90%, 80% or 50% of the nucleic acids do not have the same sequence over at least 5 consecutive nucleotides.

[0078] Assuming that the second set of nucleic acids acts as an 'index', the same set of second nucleic acids can be used with different sets of first nucleic acids representing subsets with different characteristics, that is, the second set of nucleic acids can represent a 'universal' collection of nucleic acids that can be used to identify chromosome interactions associated with different characteristics.

[0079] The first group of nucleic acids

[0080] The first group of nucleic acids is generally from a subgroup associated with an immune response. The first nucleic acid may have any of the characteristics and properties of the second group of nucleic acids mentioned herein. The first group of nucleic acids is generally derived from nucleic acids that have been treated and processed as described herein (particularly EpiSwitch TM Typically, the first set of nucleic acids represents all or at least 80% or 50% of the chromosome interactions present in the sample obtained from the individual.

[0081] Typically, the first set of nucleic acids represents a smaller population of chromosomal interactions across the loci or genes represented by the second set of nucleic acids than the chromosomal interactions represented by the second set of nucleic acids, i.e., the second set of nucleic acids represents a background or index set of interactions within a defined set of loci or genes.

[0082] Nucleic acid library

[0083] Any type of nucleic acid population mentioned herein may be in the form of a library comprising at least 200, at least 500, at least 1000, at least 5000 or at least 10000 different nucleic acids of that type, e.g. a 'first' or 'second' nucleic acid. Such a library may be in the form of a binding to an array.

[0084] Hybridization

[0085] The present invention requires a means to allow hybridization of all or part of complementary nucleic acid sequences from a first group of nucleic acids and a second group of nucleic acids. In one embodiment, in a single assay, i.e., in a single hybridization step, all first group nucleic acids are contacted with all second group nucleic acids. However, any suitable assay method may be used.

[0086] Labeled nucleic acids and hybridization patterns

[0087] Can preferably use independent mark that helps to detect successful hybridization, for example fluorophore (fluorescent molecule) or radioactive label, mark nucleic acid mentioned in this paper.Some mark can be detected under UV light.For example hybridization pattern on array as described herein, represents the difference of epigenetic chromosome interaction between two subgroups, thus provides a kind of comparative epigenetic chromosome interaction and determines which epigenetic chromosome interaction is specific to the subgroup in colony of the present invention.

[0088] The term 'hybridization pattern' broadly encompasses the presence or absence of hybridization between a first and a second group of nucleic acids, i.e. which specific nucleic acids in the first group hybridize to which specific nucleic acids in the second group, and is therefore not limited to any particular assay or technique, or requires a surface or array with a detectable 'pattern'.

[0089] Selecting subgroups with specific characteristics

[0090] The present invention provides a method comprising detecting the presence or absence of chromosome interactions, typically 5 to 20 or 5 to 500 such interactions, preferably 20 to 300 or 50 to 100 interactions, thereby determining the presence or absence of features associated with an immune response in an individual. Preferably, the chromosome interaction is a chromosome interaction in any gene mentioned herein. In one embodiment, the chromosome interaction of typing is the interaction represented by the nucleic acid in Table 1. In another embodiment, the chromosome interaction is the chromosome interaction shown in Table 13. In another embodiment, the chromosome interaction is the chromosome interaction shown in Table 16. The column titled 'Ring Detected' in the table shows which subgroup (i.e. responder or non-responder) each probe detects.

[0091] Individuals tested

[0092] Examples of species from which the tested individuals are derived are described herein. In addition, the individuals tested in the methods of the present invention may be selected in some manner. The individual may be susceptible to any of the conditions described herein and / or may require any of the therapies mentioned therein. The individual may be receiving any of the therapies mentioned herein.

[0093] In one embodiment, individuals who are tested lack a response to treatment and are tested for the purpose of discovering whether they are 'pseudo-progressors' who will respond to treatment in a second stage of the disease despite not responding in an earlier stage.

[0094] Preferred gene regions, loci, genes and chromosome interactions

[0095] For all aspects of the invention, preferred gene regions, loci, genes and chromosome interactions are mentioned in a table (e.g., Table 1). Typically in the methods of the invention, chromosome interactions are detected from at least 1, 2, 10, 50, 100, 150, 200 or 300 relevant genes listed in Table 1. Preferably, the presence or absence of at least 1, 2, 10, 50, 100, 150, 200 or 300 relevant specific chromosome interactions represented by the probe sequences in Table 1 are detected. The chromosome interaction may be upstream or downstream of any gene mentioned herein, e.g., 50 kb upstream or 20 kb downstream, e.g., from the coding sequence.

[0096] In one embodiment, at least 5, 10, 15, 20 or all chromosome interactions in Table 1.a are typed. In one embodiment, at least 5, 10, 15, 20 or all chromosome interactions in Table 1.b are typed. In one embodiment, at least 5, 10, 15, 20 or all chromosome interactions in Table 1.c are typed. In one embodiment, at least 5, 10, 15, 20 or all chromosome interactions in Table 1.d are typed. In one embodiment, at least 5, 10, 15, 20 or all chromosome interactions in Table 1.e are typed. In one embodiment, at least 5, 10, 15, 20 or all chromosome interactions in Table 1.f are typed. In one embodiment, at least 5, 10, 15, 20 or all chromosome interactions in Table 1.g are typed.

[0097] Typically, at least 5, 10, 15, 20, 30, 40 or 70 chromosome interactions are typed from any gene or region disclosed in the tables herein or portions of the tables disclosed herein. Typically, the chromosome interactions typed are present in at least 20, 50, 100, 200, 300 or all of the genes mentioned in Table 2. Typically, the chromosome interactions typed are present in at least 10, 20, 50, 70 or all of the genes mentioned in Table 3.

[0098] For all aspects of the invention, preferred gene regions, loci, genes and chromosome interactions are mentioned in Table 13. Typically, in the methods of the invention, chromosome interactions are detected from at least 1, 2, 10, 50, 100, 150, 200 or 300 relevant genes listed in Table 13. Preferably, the presence or absence of at least 1, 2, 10, 50, 100, 150, 200 or 300 relevant specific chromosome interactions represented by the probe sequences in Table 13 are detected. The chromosome interaction can be upstream or downstream of any gene mentioned herein, for example 50 kb upstream or 20 kb downstream, for example from the coding sequence.

[0099] In one embodiment, at least 5, 10, 15, 20 or all chromosome interactions in Table 13.a are typed. In one embodiment, at least 5, 10, 15, 20 or all chromosome interactions in Table 13.b are typed. In one embodiment, at least 5, 10, 15, 20 or all chromosome interactions in Table 13.c are typed. In one embodiment, at least 5, 10, 15, 20 or all chromosome interactions in Table 13.d are typed. In one embodiment, at least 5, 10, 15, 20 or all chromosome interactions in Table 13.e are typed. In one embodiment, at least 5, 10, 15, 20 or all chromosome interactions in Table 13.f are typed. In one embodiment, at least 5, 10, 15, 20 or all chromosome interactions in Table 13.g are typed. In one embodiment, at least 5, 10, 15, 20 or all chromosome interactions in Table 13.h are typed. In one embodiment, at least 5, 10, 15, 20 or all of the chromosome interactions in Table 13.i are typed.

[0100] Typically, at least 5, 10, 15, 20, 30, 40 or 70 chromosome interactions are typed from any gene or region disclosed in the table herein or a portion of a table disclosed herein. Typically, the chromosome interactions typed are present in at least 20, 50, 100, 200, 300 or all of the genes mentioned in Table 13. Typically, the chromosome interactions typed are present in at least 10, 20, 50, 70 or all of the genes mentioned in Table 13.

[0101] For all aspects of the invention, preferred gene regions, loci, genes and chromosome interactions are mentioned in Table 16. Typically, in the methods of the invention, chromosome interactions are detected from at least 1, 2, 10, 20, 30 or 40 relevant genes listed in Table 16. Preferably, the presence or absence of at least 1, 2, 10, 20, 30 or 40 relevant specific chromosome interactions represented by the probe sequences in Table 16 are detected. The chromosome interaction may be upstream or downstream of any gene mentioned herein, for example 50 kb upstream or 20 kb downstream, for example from the coding sequence.

[0102] In one embodiment, at least 5, 10 or 15 or all of the chromosome interactions in Table 18 are typed.

[0103] Typically, at least 5, 10, 15, 20, 30, 40 or 70 chromosomal interactions are typed from any gene or region disclosed in the table herein or a portion of a table disclosed herein. Typically, the chromosomal interactions typed are present in at least 20, 50, 100, 200, 300 or all of the genes mentioned in Table 13. Typically, the chromosomal interactions typed are present in at least 10, 20, 50, 70 or all of the genes mentioned in Table 13.

[0104] In one embodiment, at least 5, 10, 15, 20, 30, 40 or 70 different chromosome interactions are typed from the chromosome interactions defined in any one of Tables 1, 13 and 16. In another embodiment, at least 50%, 80% or all of the chromosome interactions typed are from Tables 1, 13 and 16.

[0105] In one embodiment, locus (including gene and / or position where chromosome interaction is detected) can include CTCF binding site.This is any sequence that can bind transcriptional repressor CTCF.The sequence can be composed of sequence CCCTC or include sequence CCCTC, which can exist with 1,2 or 3 copies at locus.CTCF binding site sequence can include sequence CCGCGNGGNGGCAG (with IUPAC notation).CTCF binding site can be located within at least 100,500,1000 or 4000 bases of chromosome interaction, or can be located within any chromosome region shown in Table 1.CTCF binding site can be located within at least 100,500,1000 or 4000 bases of chromosome interaction, or can be located within any chromosome region shown in Table 13.

[0106] In one embodiment, the chromosomal interaction detected is present in any of the gene regions shown in Table 13. In the case where a linked nucleic acid is detected in the method, a sequence shown in any of the probe sequences in Table 13 can be detected.

[0107] Therefore, usually the sequences from two regions of the probe (i.e., from two sites of chromosome interaction) can be detected. In a preferred embodiment, the probe used in the method comprises a sequence identical or complementary to the probe shown in any table, or is composed of a sequence identical or complementary to the probe shown in any table. In some embodiments, the probe used comprises a sequence homologous to any probe sequence shown in the table.

[0108] Tables provided in this article

[0109] Table 1 shows the probes representing chromosomal interactions associated with immune response (Episwitch TM Marker) data and gene data. The sequence displayed by the probe sequence can be used to detect the connection product generated from two sites of the gene region that are brought together in the chromosome interaction, that is, the probe will contain a sequence complementary to the sequence in the connection product. The first two groups of start-end positions show the probe position, and the second two groups of start-end positions show the relevant 4kb region. The following information is provided in the probe data table:

[0110] -HyperG_Stats: Discovery of significant EpiSwitches in loci based on hypergeometric enrichment parameters TM p-value of the probability of the number of markers

[0111] - Probe Count Total: EpiSwitch count tested at the locus TM The total number of conformations

[0112] - Significant Probe Count Sig: A statistically significant EpiSwitch was found at the locus TM The number of conformations

[0113] -FDR HyperG: Hypergeometric p-value corrected for multiple testing (Fimmunoresposivenesse discovery rate)

[0114] - Percent Sig: The percentage of significant EpiSwitch relative to the number of markers tested at the locus. TM The percentage of markers

[0115] -logFC: logarithm of the epigenetic ratio to base 2 (FC)

[0116] -AveExpr: Average log2 expression of probes across all arrays and channels

[0117] -T: moderated t statistic

[0118] -p-value: original p-value

[0119] -adj.p value: adjusted p value or q value

[0120] The -BB statistic (lods or B) is the log-odds (log odds) of differential gene expression.

[0121] -FC- non-log fold change

[0122] - FC_1 - non-log fold change centered around zero

[0123] -LS – Binary value related to FC_1 value. Set to -1 if FC_1 value is below -1.1, set to 1 if FC_1 value is above 1.1. Between these values, the value is 0.

[0124] Table 1 shows the genes found to have relevant chromosomal interactions. The other tables show similar data. The p-values ​​in the locus table are compared with HyperG_Stats (a parameter based on hypergeometric enrichment to find significant EpiSwitch TM The LS column shows the presence or absence of an interaction associated with a particular responder status.

[0125] The probe is designed to be 30 bp from the Taq1 site. In the case of PCR, PCR primers are usually designed to detect the ligation product, but their position from the Taq1 site may vary.

[0126] Probe location:

[0127] Start 1 - 30 bases upstream of the TaqI site on fragment 1

[0128] End 1 - TaqI restriction site on fragment 1

[0129] Start 2 - TaqI restriction site on fragment 2

[0130] End 2 - 30 bases downstream of the TaqI site on fragment 2

[0131] 4kb sequence position:

[0132] Start 1 - 4000 bases upstream of the TaqI site on fragment 1

[0133] End 1 - TaqI restriction site on fragment 1

[0134] Start 2 - TaqI restriction site on fragment 2

[0135] End 2 - 4000 bases downstream of the TaqI site on fragment 2

[0136] The GLMNET values ​​are related to fitting the entire lasso or elastic net regularization process (λ is set to 0.5 for elastic net).

[0137] Tables 1 and 4 relate to the detection of immune responses. Table 2 shows the overlap between the two studies completed, and Table 3 shows the overlap of markers associated with interferon gamma. The markers disclosed / represented in any table can be used to implement the present invention. Other tables including Tables 13 and 1 can be interpreted in a similar manner as described in Table 1 above.

[0138] Preferred embodiments of sample preparation and chromosome interaction detection

[0139] Methods for preparing samples and detecting chromosome conformation are described herein. Optimized (unconventional) versions of these methods can be used, for example, as described in this section.

[0140] Typically, the sample will contain at least 2x10 5 cells. Samples can contain up to 5x10 5 In one embodiment, the sample will contain 2x10 5 Up to 5.5x10 5 cells.

[0141] The crosslinking of epigenetic chromosome interactions present at the chromosome locus is described herein. This can be performed before cell lysis occurs. Cell lysis can be performed for 3 to 7 minutes, for example 4 to 6 or about 5 minutes. In some embodiments, cell lysis is performed for at least 5 minutes and less than 10 minutes.

[0142] Digestion of DNA with restriction enzymes is described herein. Typically, DNA restriction is performed at about 55°C to about 70°C (eg, about 65°C) for a period of about 10 to 30 minutes (eg, about 20 minutes).

[0143] Preferably, a frequent cutting restriction enzyme is used that produces ligated DNA fragments with an average fragment size of up to 4000 base pairs. Optionally, the average fragment size of the ligated DNA fragments produced by the restriction enzyme is about 200 to 300 base pairs, such as about 256 base pairs. In one embodiment, a typical fragment size is 200 base pairs to 4,000 base pairs, such as 400 to 2,000 or 500 to 1,000 base pairs.

[0144] In one embodiment of the EpiSwitch method, no DNA precipitation step is performed between the DNA restriction digestion step and the DNA ligation step.

[0145] DNA ligation is described herein. Typically, DNA ligation is performed for 5 to 30 minutes, such as about 10 minutes.

[0146] The proteins in the sample can be enzymatically digested, for example using a protease, optionally proteinase K. The proteins can be enzymatically digested for a period of about 30 minutes to 1 hour, for example about 45 minutes. In one embodiment, after protein digestion, such as proteinase K digestion, there is no cross-link reversal or phenol DNA extraction step.

[0147] In one embodiment, the PCR assay is capable of detecting a single copy of the ligated nucleic acid, preferably with a binary readout of the presence / absence of the ligated nucleic acid.

[0148] Fig.25 A preferred method for detecting chromosome interactions is shown.

[0149] Methods and uses of the present invention

[0150] The method of the present invention can be described in different ways. It can be described as a method for preparing linked nucleic acids, comprising (i) cross-linking chromosome regions that are brought together in chromosome interactions in vitro; (ii) subjecting the cross-linked DNA to cleavage or restriction digestion cleavage; and (iii) ligating the cross-linked cleaved DNA ends to form linked nucleic acids, wherein detection of the linked nucleic acids can be used to determine the chromosome status at the locus, and wherein preferably:

[0151] - the locus may be any locus, region or gene mentioned in Table 1, and / or

[0152] - wherein the chromosomal interaction may be any chromosomal interaction mentioned herein or any chromosomal interaction corresponding to any probe disclosed in Table 1, and / or

[0153] - wherein the ligation product may have or comprise (i) a sequence identical or homologous to any probe sequence disclosed in Table 1; or (ii) a sequence complementary to (ii).

[0154] The method of the present invention can be described as a method for detecting the status of chromosomes representing different subgroups in a population, comprising determining the presence or absence of chromosome interactions within defined epigenetically active regions of the genome, wherein preferably:

[0155] - Subgroups are defined by the presence or absence of an immune response, and / or

[0156] - Chromosome status can be at any locus, region or gene mentioned in Table 1; and / or

[0157] The chromosomal interaction may be any chromosomal interaction mentioned in Table 1 or corresponding to any probe disclosed in that table.

[0158] The method of the present invention can be described as a method for preparing linked nucleic acids, comprising (i) cross-linking in vitro chromosomal regions that are brought together in chromosomal interactions; (ii) subjecting the cross-linked DNA to cleavage or restriction digestion cleavage; and (iii) ligating the cross-linked cleaved DNA ends to form linked nucleic acids, wherein detection of the linked nucleic acids can be used to determine the chromosomal state at the locus, and wherein preferably:

[0159] - the locus may be any locus, region or gene mentioned in Table 13, and / or

[0160] - wherein the chromosome interaction may be any chromosome interaction mentioned herein or corresponding to any probe disclosed in Table 13, and / or

[0161] - wherein the ligation product may have or comprise (i) a sequence identical or homologous to any probe sequence disclosed in Table 13; or (ii) a sequence complementary to (ii).

[0162] The method of the present invention can be described as a method for detecting the status of chromosomes representing different subgroups in a population, comprising determining the presence or absence of chromosome interactions within defined epigenetically active regions of the genome, wherein preferably:

[0163] - Subgroups are defined by the presence or absence of an immune response, and / or

[0164] - Chromosome status can be at any locus, region or gene mentioned in Table 13; and / or

[0165] The chromosomal interaction may be any chromosomal interaction mentioned in Table 13 or corresponding to any probe disclosed in that table.

[0166] The method of the present invention can be described as a method for preparing linked nucleic acids, comprising (i) cross-linking in vitro chromosomal regions that are brought together in chromosomal interactions; (ii) subjecting the cross-linked DNA to cleavage or restriction digestion cleavage; and (iii) ligating the cross-linked cleaved DNA ends to form linked nucleic acids, wherein detection of the linked nucleic acids can be used to determine the chromosomal state at the locus, and wherein preferably:

[0167] - the locus may be any locus, region or gene mentioned in Table 16, and / or

[0168] - wherein the chromosome interaction may be any chromosome interaction mentioned herein or corresponding to any probe disclosed in Table 16, and / or

[0169] - wherein the ligation product may have or comprise (i) a sequence identical or homologous to any of the probe sequences disclosed in Table 16; or (ii) a sequence complementary to (ii).

[0170] The method of the present invention can be described as a method for detecting the status of chromosomes representing different subgroups in a population, comprising determining the presence or absence of chromosome interactions within defined epigenetically active regions of the genome, wherein preferably:

[0171] - Subgroups are defined by the presence or absence of an immune response, and / or

[0172] - Chromosome status can be at any locus, region or gene mentioned in Table 16; and / or

[0173] The chromosome interaction may be any chromosome interaction mentioned in Table 16 or corresponding to any probe disclosed in that table.

[0174] The invention includes the detection of chromosome interactions in any locus, gene or region mentioned in Table 1. The invention includes the use of nucleic acids and probes mentioned herein for detecting chromosome interactions (preferably in at least 1, 5, 10, 50, 100, 200, 250, 300 different loci or genes), such as the use of at least 1, 5, 10, 50, 100, 200, 250, 300 such nucleic acids or probes for detecting chromosome interactions. The invention includes the use of any primer or primer pair listed in Table 4 or variants of these primers as described herein (comprising primer sequences or comprising fragments and / or homologues of primer sequences) to detect chromosome interactions.

[0175] The present invention includes the detection of chromosome interactions in any locus, gene or region mentioned in Table 13. The present invention includes the use of nucleic acids and probes mentioned herein for detecting chromosome interactions (preferably in at least 1, 5, 10, 50, 100, 200, 250, 300 different loci or genes), for example, at least 1, 5, 10, 50, 100, 200, 250, 300 such nucleic acids or probes for detecting chromosome interactions. The present invention includes the use of any primer or primer pair listed in Table 13 or variants of these primers as described herein (comprising primer sequences or comprising fragments and / or sequences of homologues of primer sequences) to detect chromosome interactions.

[0176] The present invention includes detecting any locus, gene or region of chromosome interaction mentioned in Table 16. The present invention includes the use of nucleic acids and probes mentioned herein in detecting chromosome interactions (preferably in at least 1, 5, 10, 50, 100, 200, 250, 300 different loci or genes), for example, at least 1, 5, 10, 50, 100, 200, 250, 300 such nucleic acids or probes for detecting chromosome interactions. The present invention includes the use of any primer or primer pair listed in Table 17 or variants of these primers as described herein (comprising primer sequences or comprising fragments and / or sequences of homologs of primer sequences) to detect chromosome interactions.

[0177] When analyzing whether a chromosome interaction occurs 'within' a defined gene, region or location, both parts of the chromosome that are together in the interaction are within the defined gene, region or location, or in some embodiments, only a portion of the chromosome is within the defined gene, region or location.

[0178] Use of the methods of the invention for identifying new treatments

[0179] Knowledge of chromosome interactions can be used to identify new treatments for disease conditions.The present invention provides methods and uses of chromosome interactions as defined herein for identifying or designing new therapeutic agents, for example therapeutic agents related to immunotherapy.

[0180] Homologs

[0181] This article relates to homologues of polynucleotide / nucleic acid (e.g., DNA) sequences. Such homologues generally have at least 70% homology, preferably at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98% or at least 99% homology, for example, in a region of at least 10, 15, 20, 30, 100 or more continuous nucleotides, or across a nucleic acid portion from a chromosome region that participates in chromosome interactions. Homology can be calculated based on nucleotide identity (sometimes referred to as "hard homology").

[0182] Therefore, in a specific embodiment, this paper refers to the homologue of a polynucleotide / nucleic acid (e.g., DNA) sequence by reference to the sequence identity percentage. Typically, such homologues have at least 70% sequence identity, preferably at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98% or at least 99% sequence identity, for example, over a region of at least 10, 15, 20, 30, 100 or more continuous nucleotides, or across a nucleic acid portion from a chromosome region that participates in chromosome interactions.

[0183] For example, the UWGCG software package provides the BESTFIT program, which can be used to calculate homology and / or % sequence identity (e.g., using its default settings) (Devereux et al (1984) Nucleic Acids Research 12, p387-395). The PILEUP and BLAST algorithms can be used to calculate homology and / or % sequence identity and / or align sequences (e.g., identify equivalent or corresponding sequences (usually using their default settings)), for example, as described in Altschul SF (1993) J Mol Evol 36:290-300; Altschul, S, F et al (1990) J Mol Biol 215:403-10.

[0184] Software for performing BLAST analysis is publicly available through the National Center for Biotechnology Information. This algorithm involves first, by identifying in the query sequence a short word of length W that matches or satisfies a positive threshold score T when aligning words of the same length in the database sequence, identifying high-scoring sequence pairs (HSPs). T is called the neighborhood word score threshold (Altschul et al, supra). These initial neighborhood word hits serve as seeds for starting searches to find HSPs containing them. As long as the cumulative alignment score can be increased, the word hits extend in both directions along each sequence. When the following situation occurs, stop extending the word hits in each direction: the cumulative alignment score drops by a quantity X from its maximum reach value; due to the accumulation of one or more negative score residue alignments, the cumulative score becomes zero or lower; or reaches the end of any sequence. The BLAST algorithm parameters W5 T and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a wordlength (W) of 11, the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1992) Proc. Natl. Acad. Sci. USA 89:10915-10919) of 50 alignments (B), an expectation (E) of 10, M=5, N=4, and a comparison of both strands.

[0185] The BLAST algorithm performs a statistical analysis of the similarity between two sequences; see, e.g., Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5787. One similarity measure provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability that a match between two polynucleotide sequences would occur by chance. For example, a sequence is considered similar to another sequence if the smallest sum probability of a first sequence compared to a second sequence is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

[0186] Homologous sequences usually differ by 1, 2, 3, 4 or more bases, for example less than 10, 15 or 20 bases (which may be substitutions, deletions or insertions of nucleotides). These changes can be measured in any of the above regions relative to when calculating homology and / or % sequence identity.

[0187] For example, the homology of a 'pair of primers' may be calculated by treating the two sequences as one sequence (as if the two sequences were joined together) for the purpose of subsequent comparison with another primer pair, which is again treated as a single sequence.

[0188] Array

[0189] The second group of nucleic acid can be attached to the array, and in one embodiment, there are at least 15,000, 45,000, 100,000 or 250,000 kinds of different second nucleic acids attached to the array, which preferably represent at least 300, 900, 2000 or 5000 loci. In one embodiment, one or more or all different second nucleic acid colonies are combined with more than one different regions of the array, in fact repeated on the array, allowing error detection. The array can be based on the AgilentSurePrint G3 Custom CGH microarray platform. The detection of the combination of the first nucleic acid and the array can be carried out by a two-color system.

[0190] Therapeutic agents (responsiveness to which is determined according to the invention or which is selected based on a test)

[0191] Reference is made herein to therapeutic agents. The invention provides such agents for use in preventing or treating disease conditions in certain individuals, such as those diseases identified by the methods of the invention. This may comprise administering a therapeutically effective amount of the agent to an individual in need of treatment. The invention provides the use of an agent in the manufacture of a medicament for preventing or treating a disease condition in certain individuals.

[0192] The formulation of the medicament will depend on the nature of the medicament. The medicament will be provided in the form of a pharmaceutical composition comprising the medicament and a pharmaceutically acceptable carrier or diluent. Suitable carriers and diluents include isotonic saline solutions, such as phosphate buffered saline. Typical oral dosage compositions include tablets, capsules, liquid solutions and liquid suspensions. The medicament can be formulated for parenteral, intravenous, intramuscular, subcutaneous, transdermal or oral administration.

[0193] The dosage of the agent may be determined according to various parameters, in particular the substance used; the age, weight and condition of the individual being treated; the route of administration; and the desired regimen. A physician will be able to determine the route of administration and dosage required for any particular agent. However, a suitable dosage may be 0.1 to 100 mg / kg body weight, such as 1 to 40 mg / kg body weight, for example taken 1 to 3 times daily.

[0194] In one embodiment, the invention comprises detecting responsiveness to a therapeutic agent (e.g., any of the therapeutic agents mentioned herein). This can be done before treatment begins and / or during treatment.

[0195] The therapy can be monotherapy or combination therapy, such as using immune checkpoint modulators (inhibitors) of PD-1 and or its ligand PD-L1. The therapy can be a combination of anti-PD-1 or anti-PD-L1 with another drug (ipilimumab / ipilimumab) or a small molecule that targets a checkpoint such as CTLA4. The PD-1 inhibitor can be pembrolizumab (Keytruda) or nivolumab (Opdivo). The modulator or therapeutic agent of PD-L1 can be atezolizumab (Tecentriq), avelumab (Bavencio), duruvalumab (Imfinzi), CA-170, ipilimumab, tremelimumab, nivolumab, pembrolizumab, pidilizumab, BMS935559, GVAXMPDL3280A, MEDI4736, MSB0010718C, MDX-1105 / BMS-936559, AMP-224, MEDI0680.

[0196] The therapy may include administration of an agent that targets and / or modulates the interferon gamma or JAK-START pathway.

[0197] The therapeutic agent may be any such agent disclosed in any table herein (e.g., Table 9, 10, or 11), or may target any 'target' disclosed herein, including any protein disclosed in any table herein, including Table 1, 13, or 16. It should be understood that any agent disclosed in combination should also be considered to be disclosed for separate administration.

[0198] The form of the substances mentioned in this article

[0199] Any substance mentioned herein, such as nucleic acid or therapeutic agent, can be in purified or isolated form. They can be in different forms found in nature, for example, they can exist in combination with other substances, and they do not appear in nature together with the other substances. Nucleic acid (including the part of the sequence defined herein) can have a sequence different from the sequence found in nature, for example, there is at least 1,2,3,4 or more nucleotide changes in the sequence described in the homology chapters. Nucleic acid can have a heterologous sequence at 5' or 3' end. Nucleic acid can be different from the nucleic acid found in nature chemically, for example, they can be modified in some way, but preferably still can carry out Watson-Crick base pairing. Where appropriate, nucleic acid will be provided in double-stranded or single-stranded form. The present invention provides all specific nucleic acid sequences mentioned herein in single-stranded or double-stranded form, and therefore includes a complementary strand with any sequence disclosed.

[0200] The invention provides a kit for performing any of the methods of the invention, including detecting chromosome interactions associated with an immune response. Such a kit may include a specific binding agent capable of detecting the relevant chromosome interactions, such as a reagent capable of detecting the connected nucleic acids produced by the method of the invention. Preferred reagents present in the kit include probes or primer pairs capable of hybridizing with the connected nucleic acids, for example, primer pairs capable of amplifying the connected nucleic acids in a PCR reaction, as described herein.

[0201] The present invention provides a device capable of detecting relevant chromosome interactions. The device preferably includes any specific binding agent, probe or primer pair capable of detecting chromosome interactions, such as any such agent, probe or primer pair described herein.

[0202] Detection Methods

[0203] In one embodiment, quantitative detection of junction sequences associated with chromosomal interactions is performed using a probe that can be detected after being activated during a PCR reaction, wherein the junction sequence comprises sequences from two chromosomal regions that are brought together in an epigenetic chromosomal interaction, wherein the method comprises contacting the junction sequence with the probe during the PCR reaction, and detecting the degree of activation of the probe, and wherein the probe binds to the junction site. The method generally allows for detection of specific interactions in a MIQE-compliant manner using dual-labeled fluorescent hydrolysis probes.

[0204] The probe is usually labeled with a detectable marker having an inactive and an active state so that it can only be detected when activated. The degree of activation will be related to the degree of template (ligation product) present in the PCR reaction. Detection can be performed during all or part of the PCR process, for example, at least 50% or 80% of the PCR cycle.

[0205] The probe can include a fluorophore covalently attached to one end of the oligonucleotide and a quencher attached to the other end of the nucleotide. The fluorescence of the fluorophore is quenched by a quencher. In one embodiment, the fluorophore is attached to the 5' end of the oligonucleotide, and the quencher is covalently attached to the 3' end of the oligonucleotide. The fluorophore that can be used in the method of the present invention includes FAM, TET, JOE, Yakima Yellow, HEX, cyanine 3, ATTO 550, TAMRA, ROX, Texas Red, cyanine 3.5, LC610, LC 640, ATTO 647N, cyanine 5, cyanine 5.5 and ATTO 680. The quencher that can be used together with a suitable fluorophore includes TAM, BHQ1, DAB, Eclip, BHQ2 and BBQ650, optionally, wherein the fluorophore is selected from HEX, Texas Red and FAM. Preferred combinations of fluorophores and quenchers include FAM with BHQ1 and Texas Red with BHQ2.

[0206] Use of probes in qPCR assays

[0207] Hydrolysis probes of the present invention are usually optimized for temperature gradients with concentration-matched negative controls. Preferably, single-step PCR reactions are optimized. More preferably, standard curves are calculated. The advantage of using a specific probe that binds across the junction of the junction sequence is that specificity to the junction sequence can be obtained without using a nested PCR method. The methods described herein allow accurate and precise quantification of low copy number targets. The target junction sequence can be purified before the temperature gradient is optimized, such as gel purification. The target junction sequence can be sequenced. Preferably, PCR reactions are carried out using about 10ng or 5 to 15ng, or 10 to 20ng, or 10 to 50ng, or 10 to 200ng template DNA. Forward and reverse primers are designed so that one primer is bound to a sequence of one of the chromosome regions represented in the junction DNA sequence, and the other primer is bound to another chromosome region represented in the junction DNA sequence, for example, by being complementary to the sequence.

[0208] Selection of DNA targets for ligation

[0209] The invention includes selecting primers and probes for use in the PCR methods defined herein, comprising selecting primers based on their ability to bind and amplify junction sequences, and selecting probe sequences based on the properties of the target sequence to be bound, particularly the curvature of the target sequence.

[0210] Design / select probe usually to combine connection sequence, and this connection sequence is the juxtaposed restriction fragment that crosses restriction site.In one embodiment of the present invention, calculate the predicted curvature of the possible connection sequence relevant to specific chromosome interaction, for example, use the specific algorithm quoted in this paper.Curvature can be expressed as the degree of every spiral turn, for example, every spiral turn 10.5 °.Select the connection sequence for targeting, wherein the curvature tendency peak value score of this connection sequence is every spiral turn at least 5 °, typically every spiral turn at least 10 °, 15 ° or 20 °, for example every spiral turn 5 ° to 20 °.Preferably, be at least 20,50,100,200 or 400 bases, for example, 20 to 400 bases in connection site upstream and / or downstream, calculate the curvature tendency score of every spiral turn.Therefore, in one embodiment, the target sequence in connection product has any one of these curvature levels.Can also select target sequence based on minimum thermodynamic structure free energy.

[0211] Specific Implementation Methods

[0212] In one embodiment, only intrachromosomal interactions are typed / detected, and extrachromosomal interactions (between different chromosomes) are not typed / detected.

[0213] In certain embodiments, certain chromosome interactions are not typed, such as any specific interaction mentioned herein (e.g., defined by any probe or primer pair mentioned herein). In some embodiments, any gene not mentioned herein (e.g., any gene mentioned in the figure, including Figure 2 and Figure 4 Chromosomal interaction typing was performed in any or all of the genes mentioned in

[0214] In one embodiment, no chromosomal interactions represented by any or all of the probes or primers in Tables 5 to 7 are typed. In another embodiment, no chromosomal interactions present in any of the genes listed in any or all of Tables 5 to 7 are typed. In a further embodiment, no chromosomal interactions present in any of the regions listed in any or all of Tables 5 to 7 are typed.

[0215] In one embodiment, the immune response is unrelated to antibody therapy. In another embodiment, the immune response is unrelated to anti-PD-1 therapy (e.g., anti-PD-1 therapy for melanoma). In another embodiment, the immune response is unrelated to treatment of one or more of the following: blood cancer, leukemia, prostate cancer, breast cancer, diffuse large B-cell lymphoma.

[0216] Screening methods

[0217] The present invention provides a method for determining which chromosome interactions are related to the chromosome state corresponding to the immune response subgroup of a population, comprising contacting a first set of nucleic acids from subgroups having different chromosome states with a second set of index nucleic acids, and allowing complementary sequences to hybridize, wherein the nucleic acids in the first and second sets of nucleic acids represent a connection product comprising sequences from two chromosome regions that are brought together in the chromosome interaction, and wherein the hybridization pattern between the first and second sets of nucleic acids allows determination of which chromosome interactions are specific to the immune response subgroup. The subgroup may be any specific subgroup defined herein, for example with reference to a particular condition or therapy.

[0218] publication

[0219] The contents of all publications mentioned herein are incorporated into this specification by reference and may be used to further define features relevant to the present invention.

[0220] surface

[0221] Table 1 shows the final panel of markers used to test immune responsiveness.

[0222] Table 2 shows the shared markers between anti-PD-1 and anti-PD-L1 studies.

[0223] Table 3 shows markers that overlap with ORFs activated by interferon gamma.

[0224] Table 4 shows primer pairs that can be used to detect markers associated with immune response.

[0225] Tables 5 to 7 show markers, genes and regions that are not included in certain embodiments.

[0226] Table 8 shows the immune checkpoint molecules.

[0227] Table 9 provides examples of cancer therapies.

[0228] Tables 10 and 11 show combination therapies and monotherapies of certain embodiments of the invention. In some embodiments, these are therapies tested for responsiveness. In other embodiments, these therapies are given to patients based on the test results of the invention.

[0229] Table 12 provides a description of genes relevant to the present invention.

[0230] Table 13 shows another panel of markers used to test immune responsiveness.

[0231] Tables 14 and 15 describe genes relevant to embodiments of the present invention.

[0232] Tables 16 to 18 show the markers used to test immune responsiveness.

[0233] Embodiments of the present invention

[0234] Paragraph A. A method for detecting a chromosome state representing a subgroup in a population, comprising determining the presence or absence of a chromosome interaction associated with the chromosome state within a defined region of the genome, wherein the subgroup is associated with the state of an immune responsive individual; and

[0235] - wherein the chromosomal interactions are optionally determined by a method for determining which chromosomal interactions are associated with a chromosomal state corresponding to an immune response subset of a population, comprising contacting a first set of nucleic acids from subsets having different chromosomal states with a second set of index nucleic acids, and allowing complementary sequences to hybridize, wherein the nucleic acids in the first and second sets of nucleic acids represent a ligation product comprising sequences from two chromosomal regions that are brought together in the chromosomal interaction, and wherein the hybridization pattern between the first and second sets of nucleic acids allows for determination of which chromosomal interactions are specific to the immune response subset; and

[0236] - Among them, chromosomes interact:

[0237] (i) present in any of the regions or genes listed in Table 1; and / or

[0238] (ii) corresponds to any of the chromosomal interactions represented by any of the probes shown in Table 1, and / or

[0239] (iii) is present in a region of 4,000 bases that includes or flanks (i) or (ii);

[0240] or

[0241] a) present in any of the regions or genes listed in Table 13; and / or

[0242] b) corresponds to any of the chromosome interactions represented by any of the probes shown in Table 13, and / or

[0243] c) is present in a region of 4,000 bases that includes or flanks (a) or (b).

[0244] Paragraph B. The method of Paragraph A, wherein the specific combination of chromosome interactions is typed as follows:

[0245] (i) includes all chromosome interactions represented by the probes in Table 1; and / or

[0246] (ii) comprises at least 10, 50, 100, 150, 200 or 300 chromosome interactions represented by the probes in Table 1; and / or

[0247] (iii) present together in at least 10, 50, 100, 150 or 200 regions or genes listed in Table 1; and / or

[0248] (iv) wherein at least 10, 50, 100, 150, 200 or 300 chromosomal interactions are typed that are present in a 4,000 base region that includes or flanks the chromosomal interactions represented by the probes in Table 1.

[0249] Paragraph C. The method of Paragraph A, wherein the specific combination of chromosome interactions is typed as follows:

[0250] (i) comprises all chromosome interactions represented by the probes in Table 13; and / or

[0251] (ii) comprises at least 10, 50, 100, 150, 200 or 300 chromosome interactions represented by the probes in Table 13; and / or

[0252] (iii) present together in at least 10, 50, 100, 150 or 200 regions or genes listed in Table 13; and / or

[0253] (iv) wherein at least 10, 50, 100, 150, 200 or 300 chromosomal interactions are typed that are present in a 4,000 base region that includes or flanks the chromosomal interactions represented by the probes in Table 13.

[0254] D. A method according to any of the preceding paragraphs, wherein the chromosomes interact:

[0255] - typing in a sample from an individual, and / or

[0256] - by detecting the presence or absence of DNA loops at sites of chromosome interaction, and / or

[0257] - by detecting the presence or absence of distal regions of chromosomes that are clustered together within the chromosome conformation, and / or

[0258] Typing by detecting the presence of linked nucleic acids which are generated during said typing and whose sequence comprises two regions each corresponding to a chromosomal region brought together in a chromosomal interaction, wherein the detection of the linked nucleic acids is preferably performed by using:

[0259] (i) a probe having at least 70% identity to any of the specific probe sequences mentioned in Table 1, and / or (ii) a primer pair having at least 70% identity to any of the primer pairs in Table 4; or

[0260] (a) a probe having at least 70% identity to any of the specific probe sequences mentioned in Table 13, and / or (b) a primer pair having at least 70% identity to any of the primer pairs in Table 13.

[0261] E. A method according to any of the preceding paragraphs, wherein:

[0262] - the second set of nucleic acids is from a larger group of individuals than the first set of nucleic acids; and / or

[0263] - the first set of nucleic acids is from at least 8 individuals; and / or

[0264] - the first set of nucleic acids is derived from at least 4 individuals of a first subgroup and at least 4 individuals of a second subgroup, the second subgroup preferably not overlapping with the first subgroup; and / or

[0265] - performing the method to select an individual for medical treatment; and / or

[0266] - The immune response is in response to immunotherapy or immune checkpoint therapy; and / or

[0267] - The immune response is in response to cancer immunotherapy, and / or

[0268] - said method is performed to determine the immune response at one or more defined time points, wherein optionally at least one time point is during the course of treatment.

[0269] F. A method according to any of the preceding paragraphs, wherein:

[0270] - the second group of nucleic acids represents an unselected group; and / or

[0271] - wherein the second set of nucleic acids is bound to the array at defined locations; and / or

[0272] - wherein the second set of nucleic acids represents chromosomal interactions among at least 100 different genes; and / or

[0273] - wherein the second set of nucleic acids comprises at least 1,000 different nucleic acids representing at least 1,000 different chromosomal interactions; and / or

[0274] - wherein the first group of nucleic acids and the second group of nucleic acids comprise at least 100 nucleic acids having a length of 10 to 100 nucleotide bases.

[0275] G. A method according to any of the preceding paragraphs, wherein the first set of nucleic acids is obtainable in a method comprising the steps of: -

[0276] (i) cross-linking of chromosomal regions that come together in chromosomal interactions;

[0277] (ii) subjecting the cross-linked regions to cleavage, optionally by restriction digestion using an enzyme; and

[0278] (iii) ligating the cross-linked cleaved DNA ends to form a first set of nucleic acids (particularly comprising ligated DNA).

[0279] H. A method according to any of the preceding paragraphs:

[0280] - wherein preferably at least 10 to 200 different chromosome interactions are typed in 10 to 200 different regions or genes; and optionally (a) 50 to 100 different chromosome interactions are typed, each of which is located in a different gene and / or a different region as defined in Table 1; or (b) 50 to 100 different chromosome interactions are typed, each of which is located in a different gene and / or a different region as defined in Table 13;

[0281] and / or

[0282] - It is performed to select whether an individual receives immunotherapy, wherein the immunotherapy preferably comprises small molecule immunotherapy, antibody immunotherapy or cellular immunotherapy.

[0283] I. The method according to any of the preceding paragraphs, wherein the defined region of the genome:

[0284] (i) comprises a single nucleotide polymorphism (SNP); and / or

[0285] (ii) expression of microRNA (miRNA); and / or

[0286] (iii) expression of non-coding RNA (ncRNA); and / or

[0287] (iv) expressing a nucleic acid sequence encoding at least 10 consecutive amino acid residues; and / or

[0288] (v) expression regulatory elements; and / or

[0289] (vii) contains a CTCF binding site.

[0290] J. The method according to any of the preceding paragraphs, performed to identify or design a therapeutic agent for immunotherapy;

[0291] - wherein the method is preferably used to detect whether a candidate agent can cause a change in chromosome state associated with different levels of immune response;

[0292] - wherein the chromosome interaction is represented by any probe in Table 1; and / or

[0293] - Chromosomal interactions are present in any of the regions or genes listed in Table 1;

[0294] and wherein, optionally:

[0295] - the chromosome interactions are determined by the method for determining which chromosome interactions are associated with the chromosome state as defined in claim 1, and / or

[0296] - Monitoring changes in chromosome interactions using (i) probes having at least 70% identity to any of the probe sequences mentioned in Table 1, and / or (ii) primer pairs having at least 70% identity to any of the primer pairs in Table 4.

[0297] K. The method according to any of the preceding paragraphs, performed to identify or design a therapeutic agent for immunotherapy;

[0298] - wherein the method is preferably used to detect whether a candidate agent can cause a change in chromosome state associated with different levels of immune response;

[0299] - wherein the chromosome interaction is represented by any probe in Table 13; and / or

[0300] - Chromosomal interactions are present in any of the regions or genes listed in Table 13;

[0301] and wherein, optionally:

[0302] - the chromosome interactions are determined by the method for determining which chromosome interactions are associated with the chromosome state as defined in claim 1, and / or

[0303] - Monitoring changes in chromosome interactions using (i) a probe having at least 70% identity to any of the probe sequences mentioned in Table 13, and / or (ii) a primer pair having at least 70% identity to any of the primer pairs in Table 13.

[0304] L. A method according to paragraph J or K, comprising selecting a target based on detection of chromosomal interactions, and preferably screening modulators of the target to identify therapeutic agents for immunotherapy, wherein the target is optionally a protein.

[0305] M. A therapeutic agent for use in a method of immunotherapy of an individual identified as being in need of the therapeutic agent by the method according to any of paragraphs A to I.

[0306] N. A method according to any of paragraphs A to K or a therapeutic agent for use according to paragraph M, wherein typing or detecting comprises specifically detecting the ligation product by quantitative PCR (qPCR), wherein the quantitative PCR uses primers capable of amplifying the ligation product and a probe that binds to the ligation site during the PCR reaction, wherein the probe comprises a sequence complementary to a sequence from each of the chromosomal regions that are brought together in the chromosomal interaction, wherein preferably the probe comprises:

[0307] An oligonucleotide that specifically binds to the ligation product, and / or

[0308] A fluorophore covalently linked to the 5' end of the oligonucleotide, and / or

[0309] a quencher covalently attached to the 3' end of the oligonucleotide, and

[0310] Optionally,

[0311] The fluorophore is selected from HEX, Texas Red and FAM; and / or

[0312] The probe comprises a nucleic acid sequence of 10 to 40 nucleotide bases in length, preferably 20 to 30 nucleotide bases in length.

[0313] Specific Implementations

[0314] EpiSwitch TM The platform technology detects epigenetic regulatory signatures that indicate regulatory changes between normal and abnormal conditions at a locus. TM The platform determines and monitors the fundamental epigenetic level of gene regulation associated with the regulatory higher-order structure of human chromosomes (also known as chromosome conformation signatures). Chromosome signatures are unique primary steps in the gene deregulation cascade. They are high-order biomarkers with a range of unique advantages over biomarker platforms that utilize later epigenetic and gene expression biomarkers (such as DNA methylation and RNA profiling).

[0315] EpiSwitch TM Array assay

[0316] Custom EpiSwitch TM The array screening platform has four unique chromosome conformations with densities of 15K, 45K, 100K and 250K, and each chimeric fragment is repeated 4 times on the array, making the effective densities 60K, 180K, 400K and 1 million, respectively.

[0317] Custom Designed EpiSwitch TM Array

[0318] 15K EpiSwitch TM Arrays can screen the entire genome, including using EpiSwitch TM EpiSwitch is a biomarker discovery technology that interrogates approximately 300 loci. TM The arrays are based on the Agilent SurePrint G3 custom CGH microarray platform; this technology offers four densities, 60K, 180K, 400K, and 1 million probes. TM Probes were presented in quadruplicate, so the density of each array was reduced to 15K, 45K, 100K, and 250K, allowing statistical evaluation of reproducibility. Potential EpiSwitch for each genetic locus queried TM The average number of markers was 50; therefore, the number of loci that could be investigated was 300, 900, 2000, and 5000.

[0319] EpiSwitch TM Custom array pipeline

[0320] EpiSwitch TM The array is a two-color system that allows a group of samples to be TM After library generation, it was labeled in Cy5, while other samples to be compared / analyzed (controls) were labeled in Cy3. The arrays were scanned using an Agilent SureScan scanner and the resulting features were extracted using Agilent Feature Extraction Software. TM The array processing script processed the data. The arrays were processed using the standard two-color package in Bioconductor in R: Limma*. Normalization of the arrays was done using the normalize_array function in Limma* and relative to the on-chip Agilent positive control and EpiSwitch TM Positive control was performed. Data were filtered based on Agilent flag calls, Agilent control probes were removed, and technical replicate probes were averaged for analysis using Limma*. Probes were modeled based on the difference between the 2 scenarios compared and then corrected using the false discovery rate. Probes with p<=0.1FDR p-value, coefficient of variation (CV)<=30% were used for further screening. To reduce the probe set, multifactorial analysis was further performed using the FactorMineR package in R.

[0321] *Note: LIMMA is a linear model and empirical Bayes procedure for assessing differential expression in microarray experiments. Limma is an R package for analyzing gene expression data generated by microarrays or RNA-Seq.

[0322] The probe pool was initially selected based on adjusted p-values, and the final pick was based on FC and CV < 30% (arbitrary cutoff) parameters. Further analysis and the final list were derived based only on the first two parameters (adj. p-value; FC).

[0323] Statistics pipeline

[0324] Using EpiSwitch in R TM Analysis software package processing EpiSwitch TM Screening arrays to select high-value EpiSwitch TM Markers to translate to EpiSwitch TM On the PCR platform.

[0325] Step 1

[0326] Probes were selected based on the corrected p-value (false discovery rate, FDR), which is the product of the modified linear regression model. Probes below p-value <= 0.1 were selected and then further reduced by epigenetic ratio (ER), probe ER must be <= -1.1 or => 1.1, in order to be selected for further analysis. The final filter was the coefficient of variation (CV), probes must be below <= 0.3.

[0327] Step 2

[0328] The top 40 markers were selected from the statistical list based on their ER to be selected as markers for PCR translation. The top 20 markers with the highest negative ER loading and the top 20 markers with the highest positive ER loading formed the list.

[0329] Step 3

[0330] The markers obtained from step 1 (statistically significant probes) formed the basis for enrichment analysis using hypergeometric enrichment (HE). This analysis allowed the markers to be reduced from the list of significant probes and together with the markers from step 2 formed the translation to EpiSwitch TM List of probes on the PCR platform.

[0331] HE processes statistical probes to determine which genetic positions have an enrichment of statistically significant probes, indicating which genetic positions are hubs of epigenetic differences.

[0332] The most significantly enriched loci based on corrected p-values ​​were selected to generate probe lists. Genetic positions with p-values ​​below 0.3 or 0.2 were selected. Statistical probes mapped to these genetic positions were combined with markers from step 2 to form the EpiSwitch TM High value markers for PCR translation.

[0333] Array design and processing

[0334] Array design

[0335] 1. Use SII software (currently v3.2) to process genetic loci to:

[0336] a. Extract the genomic sequence at these specific genetic loci (with 50 kb upstream and 20 kb downstream gene sequences)

[0337] b. Define the probability that the sequences in this region participate in CCs

[0338] c. Use specific RE cleavage sequence

[0339] d. Determine which restriction fragments are likely to interact in a particular orientation

[0340] e. Rank the likelihood of different CCs interacting together.

[0341] 2. Determine the array size and hence the number of available probe positions (x)

[0342] 3. Extract x / 4 interactions.

[0343] 4. For each interaction, define a 30 bp sequence to the restriction site in part 1 and a 30 bp sequence to the restriction site in part 2. Check if those regions are duplicates, if not, exclude and take the next interaction in the list. Join the two 30 bp to define the probe.

[0344] 5. Create a list of x / 4 probes plus defined control probes and replicate 4 times to create the list to be created on the array.

[0345] 6. Upload the probe list to the Agilent Sure design website to customize the CGH array.

[0346] 7. Design of Agilent custom CGH arrays using probe sets.

[0347] Array processing

[0348] 1. Use EpiSwitch TM Standard operating procedures (SOPs) process samples for template production.

[0349] 2. Clean up by ethanol precipitation by the array processing laboratory.

[0350] 3. Process samples according to the Agilent SureTag Complete DNA Labeling Kit – This kit is an Agilent oligonucleotide array-based CGH kit for enzymatic labeling of genomic DNA analysis from blood, cells, or tissues.

[0351] 4. Scanning was performed using an Agilent C scanner and Agilent feature extraction software.

[0352] EpiSwitchTM

[0353] The EpiSwitchTM biomarker signature has demonstrated high robustness, sensitivity, and specificity in stratifying complex disease phenotypes. The technology leverages recent breakthroughs in epigenetic science to monitor and assess chromosome conformation signatures as highly informative epigenetic biomarkers. Current research methods conducted in academic settings require 3 to 7 days to biochemically process cellular material for the detection of CCS. Those procedures have limited sensitivity and reproducibility; and cannot be derived from EpiSwitch during the design phase. TM Benefit from the targeted insights provided by analytics packages.

[0354] EpiSwitch TM Array in silico marker determination

[0355] Via EpiSwitch TM The array evaluates CCS loci across the genome directly on clinical samples from the test population to identify all relevant stratification lead biomarkers. TM Array platforms were used for marker determination due to their high throughput capabilities, and their ability to rapidly screen large numbers of loci. The arrays used were Agilent custom CGH arrays, which allow interrogation of markers determined by computer software.

[0356] EpiSwitch TM PCR

[0357] Then, through EpiSwitch TM PCR or DNA sequencer (i.e. Roche 454, Nanopore MinION, etc.) validation by EpiSwitch TM Potential markers identified by array. Top PCR markers that were statistically significant and showed the best reproducibility were selected for further reduction to the final EpiSwitch TM The signature set was validated in an independent sample cohort.TM PCR can be performed by trained technicians following established SOP protocols. All protocols and manufacturing of reagents are performed in accordance with ISO 13485 and 9001 certification to ensure quality of work and ability to transfer protocols. EpiSwitch TM PCR and EpiSwitch TM The array biomarker platform is compatible with both whole blood and cell line analysis. The test is sensitive enough to detect very low copy number abnormalities using small amounts of blood.

[0358] Example

[0359] In the first study, melanoma patients were treated with anti-PD-1 (pembrolizumab) for 12 weeks. First, their epigenetic status measured by EpiSwitch was assessed at baseline before treatment and then at week 12, with a clinical readout of response or non-response. We then screened, evaluated, and validated a subset of 3D genome structural profiles, chromosome conformation signatures, at baseline to identify profiles at 332 genetic positions across the genome that were beneficial for response or non-response to treatment. These were evaluated on the EpiSwitch array, looking at local multiple 3C interactions at those genetic positions in technical and biological replicates, comparing samples from responders and non-responders at baseline. More than 14,000 EpiSwitch markers were evaluated directly on the array. The best markers were translated to PCR and evaluated in an independent patient cohort.

[0360] Figure 1 An example of clinical annotations for patients used in this study is shown. Color coded markers: Patients listed in red were used for array screening. Patients listed in blue were used as part of an independent cohort for validation – these patients were not used for marker selection, which is important for developing robust biomarkers. Clinical assessment of response or non-response was defined by standard RESIST 1.1 guidelines.

[0361] Phase 1 consisted of initial array screening and evaluation of 14,000 marker leads (all predicted by pattern recognition). Phase 2 was translation of statistically significant marker leads from array to PCR. Further evaluation of markers via PCR by regression analysis was performed to reduce the number of final markers in the final signature. Phase 3 was validation of the final signature of the 6 best biomarkers (e.g. Figure 2 shown). Figure 2 The table in shows the names of the best biomarkers and the genetic loci where they are located, i.e., where they contribute to overall regulation in a specific way.

[0362] Figure 3Shown is a Venn diagram of the best predictive biomarker from the array analysis (comparing baseline to responders and non-responders) and the best response biomarker (comparing responders at baseline and week 12). The overlap not only gives good response biomarkers that are present at the start of response, but can also be monitored over the 12 weeks.

[0363] Figure 4 is an example of a binary PCR readout for some of the final signature biomarkers for an individual patient: 1CCs is present, 0CCs is absent. The difference in the profiles of responders and non-responders can be seen visually. R is responder. NR is non-responder.

[0364] Figure 5 Two groups of lung cancer patients treated with anti-PD-L1 monoclonal antibodies are shown. Blood was collected at baseline (BL) before treatment and two weeks (2W) after starting treatment. The identities of the two groups for response were determined, but in the initial study, the blinded division into Group I and Group II was performed. In all patients listed, the best top 30 PCR-based markers leading to predict response to anti-PD-1 from the first study were evaluated (see above).

[0365] Figure 6 Statistical analysis of the best top 13 statistically significant markers discriminating between groups I and II is shown. PDCD1LG2 and STAT5 were also the main discriminating markers in the original anti-PD-1 study: PDCD1LG2 for non-responders and STAT5B for responders. This helped to correctly identify groups I and II as responder and non-responder groups. The biomarkers monitor dysregulation triggered by PD-1 in the first study or its ligand PD-L1 in the second study in the same immunotherapy checkpoint cell network and thus have shared features with overlap on the same markers – 6 non-responder markers, 7 responder markers from the first PD-1 study were still valid in the second study using PD-L1.

[0366] Figure 7 shows a principal component analysis (PCA) of the top 13 markers selected from the PD-L1 cohort. This is a 3DPCA that shows good separation of responders and non-responders on the first three components of stratification. It is noteworthy that for the same patients, non-responders (black triangles) are also separated between baseline (A) and 2 weeks of treatment (B). This is an independent feature related to the tightness of control of epigenetic distribution in responders and non-responders.

[0367] Figure 8Shown is how in a separate third study conducted on lung cancer patients using different anti-PD-L1 monoclonal antibodies, 15 patient baseline samples were provided as blinded for annotation of response / non-response to treatment. Combining the first and second studies, using 8 patients from the first study (PD-1 treatment of melanoma) and 24 patients from the second study (different PD-L1 for lung cancer), a panel of markers was evaluated and then the top 5 markers with statistical significance (listed in the table) were used for classification of the 15 blinded samples.

[0368] Fig. 9 It shows how a random forest classifier built on the 5 markers listed produced predicted calls (prediction column) for each of the 15 samples. Fig.10 Comparison of the prediction calls for each sample with the unblinded validation (actual column) is shown. The stratification efficiency is listed in the table. Sensitivity 71%, specificity 87.5%, positive predictive value 83% (important in the context of patient selection), negative predictive value 77%.

[0369] Fig.11 The standard rOC curve of the classifier is shown. AUC = 0.786

[0370] Fig.12 The principal component analysis of all samples used in this analysis is shown: 8 from the first study, 24 from the second study, and 15 from validation. The separation of responders and non-responders is already clear on the first principal component. For all 47 samples, there were only two samples that were misclassified in the open classifier.

[0371] The third study involved anti-PD-L1 therapy in lung cancer. During the array phase of screening, 12 responders and 12 non-responders were compared at baseline on the array, with a total of 180,000 reads (in the form of technical and biological replicates). The top 100 markers from the array were then PCR translated and then validated.

[0372] The marker leads from the PD-1 (Study I), PD-L1 (Study II) arrays were compared to the marker lead from the PD-L1 Study III array. Fig.13 Overlap of the 2522 leaders common to responders is shown. Fig.14 The display is the same, but now looking at the most statistically significant – responders 276 common significant antecedents from both studies (Study I on the left, Study II on the right). Fig.15 The same is shown, but for its non-responders, there is only one (Study I on the left, Study II on the right).

[0373] Fig.16Shown are how the genetic loci of array readouts for response and non-response markers (Studies I and III) overlap with genes involved in the interferon gamma pathway. Interferon gamma treatment increases PD-L1 expression, a clinical observation for susceptibility to treatment response. Fig.17 The same content is shown, but only for statistically significant data. Fig.18 The same results are shown, but for all studies I-III.

[0374] Fig.19 Venn diagrams of four cohorts are shown: loci (ORFs) of the INFG pathway, anti-PD-L1 responders and non-responders, all anti-PD-1.

[0375] Fig. 20 Venn diagrams of four cohorts are shown: loci (ORFs) of the INFG pathway, anti-PD-1 responders and non-responders, all anti-PD-L1.

[0376] Fig.21 The loci for all responder markers shared between studies I-III and the INFG genes are shown. Figure 22 shows the same content, but the 95 loci listed contain some significant responder EpiSwitch markers shared between all three studies I-III. Figure 23 shows the loci list of Figure 22, showing the number of significant marker leads and the total number of marker leads when these loci were evaluated on the array. Fig.24 Shows significant EpiSwitch with aPD-L1 TM CCS-related ORFs matching interferon signaling pathway.

[0377] Having established common epigenetic settings as markers of responders to PD-1 and PD-L1 therapy, we traced the genetic loci observed under control of epigenetic settings to their protein products and investigated the network relationships of these proteins in the context of known protein-protein networks and their functional roles. Overexpression of genetic loci affected by responsive EpiSwitch markers onto the String database network indicated that epigenetically controlled proteins in responders participate in tight networks associated with two functions: immune response regulation, cell surface receptor signaling pathways, and regulation of T cell activation.

[0378] Specific conclusions

[0379] Markers have been identified that have statistically significant disseminating ability to identify patients who have established a good response to immunotherapy (including immune checkpoint therapy) (i.e., responders) and patients who have not established a response (i.e., non-responders or progressors) at baseline. The markers in Table 1 represent the common prevalence of responders in three independent cohorts of patients with melanoma or lung cancer (NSCLC). Melanoma patients were treated with PD-1 (pembrolizumab) and NSCLC was treated with two different PD-L1s. These are agnostic markers that predict treatment and are present in different types of cancer. There is also an important agnostic and universal predictive marker for non-response between the PD-L1 and PD-L2 loci.

[0380] The list of markers in Table 1 reflects common network modulation in responders. These can be used as agnostic markers to monitor response / non-response under various treatments and conditions, including response to treatments targeting standard immune checkpoint molecules that control immunological network responses.

[0381] Further work

[0382] Continued identification of targets for epigenetic changes based on chromosome conformation signatures (CCS) will enable the selection of a priori patients who are likely to respond to anti-PD-1 therapy alone or in combination for the treatment of non-small cell lung cancer (NSCLC). TM The PCR platform was used to screen EpiSwitch targets discovered from this array in samples from patients at baseline who were treated with three immunotherapy arms, two anti-PD-L1 therapies and one anti-PD-1 therapy (pembrolizumab). TM Markers were screened and validated. Two anti-PD-L1 responsive CCS were developed in NSCLC patients, and pembrolizumab responsive CCS were developed in melanoma patients and further validated in NSCLC patients. Tables 13, 16, and 18 provide the results of further work and show another set of markers that can be used to determine immune responsiveness.

[0383] Study Design

[0384] In the metastatic melanoma study, a total of 32 peripheral blood mononuclear cell (PBMC) samples from 16 patients with metastatic melanoma were studied. These patients had received anti-PD1 therapy. Patients were evaluated at 2 time points, baseline assessment and 12-week tumor assessment. A total of 16 samples were used in the discovery phase using the EpiSwitch array. The top 100 EpiSwitch markers identified from the array screening were validated in baseline and 12-week samples to identify response and pharmacodynamic effects to anti-PD1 therapy. The top-ranked EpiSwitch markers were classified into two groups: responders and non-responders to anti-PD-1 therapy.

[0385] In the NSCLC study, a total of 16 baseline PBMCs from patients with non-small cell lung cancer (NSCLC) treated with anti-PD-L1 therapy were studied. TM Predictive markers. The aim of this project is to confirm the predictive power of EpiSwitch markers common to both anti-PD-1 and anti-PD-L1 predictive profiles in patients with NSCLC who have been treated with anti-PD-L1 therapy at baseline.

[0386] Probe Locus Total probe count 1 ORF293_6_32634077_32639503_32662361_32664960_FR HLA-DQA1 28 2 ORF241_10_88946200_88948398_88998943_89014190_FF FAS 50 3 ORF293_6_32626930_32634077_32662361_32664960_RR HLA-DQA1 28 4 ORF38_13_111255999_111262146_111317973_111320769_FF ARHGEF7 122 5 ORF226_1_94522204_94526809_94565070_94571537_RR F3 36 6 ORF553_7_6325447_6327369_6392091_6396545_RR RAC1 64 7 ORF705_9_114882931_114894596_114957908_114962933_FR TNFSF8 50 8 ORF441_5_68187850_68194388_68215410_68221074_FR PIK3R1 148 9 IKBKB_8_42264241_42271203_42302441_42304680_FF IKBKB 46 10 ORF703_1_6461604_6466207_6481328_6484248_FF TNFRSF25 68 11 ORF38_13_111170222_111182176_111317973_111320769_FF ARHGEF7 122 12 PRR5_22_44662780_44666500_44696835_44701888_FF PRR5 64 13 ORF531_22_44662780_44666500_44696835_44701888_FF PRR5 64 14 ORF501_5_68215410_68221074_68272048_68277769_RF PIK3R1 148 15 TNFRSF25_1_6461604_6466207_6481328_6484248_FF TNFRSF25 68 16 C8A_1_56824227_56829583_56902220_56908104_FR C8A 166 17 ORF76_2_241559192_241566423_241577996_241581000_RR BOK 44 18 IKBKB_8_42264241_42271203_42331044_42332799_FR IKBKB 46 19 BOK_2_241559192_241566423_241577996_241581000_RR BOK 44 20 ORF464_6_44270723_44274914_44307667_44312139_RF NFKBIE 44 21 TNFRSF25_1_6461604_6466207_6514024_6515315_FR TNFRSF25 68 22 PIK3R1_5_68195469_68198352_68215410_68221074_RR PIK3R1 148 23 ORF698_18_62330039_62332469_62356961_62362521_FR TNFRSF11A 58 24 ORF307_8_42264241_42271203_42331044_42332799_FR IKBKB 46 25 CD82_11_44526701_44529279_44592038_44600902_RF CD82 50 26 ORF703_1_6461604_6466207_6494588_6498048_FF TNFRSF25 68 27 ORF307_8_42264241_42271203_42302441_42304680_FF IKBKB 46 28 TNFRSF25_1_6461604_6466207_6494588_6498048_FF TNFRSF25 68 29 CASP6_4_109703339_109705583_109735036_109741090_RF CASP6 28

[0387] Table 1.a1

[0388]

[0389]

[0390] Table 1.a2

[0391] t P-value adj.P. value B FC FC_1 1 -2.980618242 0.01344665400 0.040517443 -3.620544416 0.639689949 -1.563257327 2 -6.24344027 0.00008620000 0.001125209 1.58573085 0.648078185 -1.543023701 3 -3.580221478 0.00482085800 0.018832070 -2.583272553 0.711482673 -1.405515606 4 -22.94378205 0.00000000038 0.000001590 13.50068753 0.72031744 -1.388276813 5 -6.068793285 0.00010890800 0.001320738 1.342264192 0.738948493 -1.353274294 6 -5.571884831 0.00021663700 0.002075220 0.625787741 0.740843647 -1.34981248 7 -6.927544857 0.00003590000 0.000632929 2.498799383 0.749563705 -1.33410942 8 -16.24057806 0.00000001200 0.000010700 10.48782055 0.759820695 -1.316099977 9 -17.46788221 0.00000000585 0.000010100 11.15054812 0.761252236 -1.313625041 10 -9.736436082 0.00000168000 0.000107198 5.651749271 0.762306283 -1.311808681 11 -17.0031469 0.00000000765 0.000010700 10.90661915 0.762918893 -1.310755324 12 -17.18527923 0.00000000688 0.000010600 11.00320387 0.765257487 -1.30674971 13 -15.39183699 0.00000002050 0.000013100 9.992593359 0.765282901 -1.306706316 14 -16.16361934 0.00000001260 0.000010700 10.44421723 0.766259665 -1.305040636 15 -11.77686613 0.00000027700 0.000044500 7.465604014 0.770999521 -1.297017667 16 -10.68867959 0.00000070000 0.000068900 6.540229405 0.771621904 -1.295971504 17 -11.11416276 0.00000048300 0.000057900 6.912800589 0.775013085 -1.290300795 18 -16.40706083 0.00000001090 0.000010700 10.58128991 0.777477774 -1.286210402 19 -10.9324899 0.00000056500 0.000062000 6.755470255 0.77782441 -1.285637205 20 -19.65763701 0.00000000180 0.000005770 12.19684795 0.778594689 -1.284365299 21 -10.66682351 0.00000071300 0.000069500 6.520700487 0.779763527 -1.282440079 22 -14.85687535 0.00000002900 0.000015300 9.663464141 0.78101738 -1.280381239 23 -2.587519517 0.02657975500 0.067536623 -4.295830899 0.783634368 -1.276105338 24 -16.6498587 0.00000000942 0.000010700 10.71553998 0.785433249 -1.273182669 25 -12.64682486 0.00000014000 0.000033200 8.144494866 0.785552353 -1.272989631 26 -12.44559121 0.00000016300 0.000035700 7.991924175 0.786188466 -1.271959642 27 -16.03607714 0.00000001370 0.000010900 10.37139589 0.786394357 -1.271626622 28 -12.06306132 0.00000022000 0.000039400 7.6945755 0.788809824 -1.26773269 29 -13.55417084 0.00000007120 0.000022100 8.801357166 0.790363029 -1.265241367

[0392] Table 1.a3

[0393]

[0394]

[0395] Table 1.a4

[0396]

[0397]

[0398] Table 1.a5

[0399]

[0400] Table 1.a6

[0401]

[0402]

[0403] Table 1.b1

[0404]

[0405]

[0406] Table 1.b2

[0407]

[0408]

[0409] Table 1.b3

[0410]

[0411]

[0412]

[0413] Table 1.b4

[0414]

[0415] Table 1.b5

[0416]

[0417]

[0418] Table 1.b6

[0419]

[0420]

[0421] Table 1.c1

[0422]

[0423]

[0424] Table 1.c2

[0425]

[0426]

[0427] Table 1.c3

[0428]

[0429]

[0430]

[0431] Table 1.c4

[0432]

[0433]

[0434] Table 1.c5

[0435]

[0436]

[0437] Table 1.c6

[0438]

[0439]

[0440] Table 1.d1

[0441]

[0442]

[0443] Table 1.d2

[0444]

[0445]

[0446] Table 1.d3

[0447]

[0448]

[0449]

[0450] Table 1.d4

[0451]

[0452]

[0453] Table 1.d5

[0454]

[0455]

[0456] Table 1.d6

[0457]

[0458]

[0459] Table 1.e1

[0460]

[0461]

[0462] Table 1.e2

[0463]

[0464]

[0465] Table 1.e3

[0466]

[0467]

[0468]

[0469] Table 1.e4

[0470]

[0471]

[0472] Table 1.e5

[0473]

[0474]

[0475] Table 1.e6

[0476]

[0477]

[0478] Table 1.f1

[0479]

[0480]

[0481] Table 1.f2

[0482]

[0483]

[0484] Table 1.f3

[0485]

[0486]

[0487]

[0488] Table 1.f4

[0489]

[0490]

[0491] Table 1.f5

[0492]

[0493]

[0494] Table 1.f6

[0495]

[0496]

[0497] Table 1.g1

[0498]

[0499]

[0500] Table 1.g2

[0501] t P-value adj.P. value B FC FC_1 320 -3.28569851 0.00795229900 0.027348446 -3.091904234 0.920935326 -1.08585258 321 -5.515807304 0.00023462500 0.002190731 0.542703708 0.920948045 -1.085837584 322 -5.826586351 0.00015163300 0.001635661 0.997453523 0.921246632 -1.085485651 323 -5.468019963 0.00025121700 0.002297775 0.471544728 0.92129862 -1.085424398 324 -4.149900419 0.00187961300 0.009459704 -1.616672944 0.921548181 -1.085130459 325 -5.560189598 0.00022026300 0.002097026 0.608497575 0.921615937 -1.085050681 326 -2.849923133 0.01686220500 0.048027440 -3.846341043 0.92185263 -1.084772085 327 -4.624546759 0.00088526700 0.005497061 -0.837900587 0.921986273 -1.084614847 328 -4.850787441 0.00062519600 0.004318657 -0.476920106 0.921988599 -1.084612111 329 -5.670796723 0.00018840600 0.001897248 0.771230471 0.922042483 -1.084548726 330 -4.321578858 0.00142644200 0.007770947 -1.331816291 0.922053542 -1.084535718 331 -5.531878455 0.00022931200 0.002158503 0.566560929 0.922342397 -1.084196068 332 -3.011085086 0.01275662000 0.038978718 -3.567805275 0.922414107 -1.084111781 333 -2.85057896 0.01684304500 0.047979425 -3.845210285 0.922583427 -1.083912816 334 -4.025458886 0.00230126300 0.010935916 -1.825213078 0.92266 -1.08382286 335 -3.603776786 0.00463332800 0.018277657 -2.542780708 0.922727147 -1.08374399 336 -5.245214347 0.00034694100 0.002861465 0.135432481 0.922794256 -1.083665176 337 -3.614904266 0.00454738300 0.018046224 -2.523664746 0.922795192 -1.083664077 338 -6.491621867 0.00006230000 0.000903821 1.924369043 0.922919249 -1.083518413 339 -4.570910561 0.00096238300 0.005851655 -0.924484832 0.922952992 -1.0834788 340 -4.368296497 0.00132418300 0.007358200 -1.254903515 0.923057091 -1.083356609 341 -2.392253605 0.03725465400 0.087236543 -4.624664393 0.923207505 -1.083180103 342 -3.586023328 0.00477395000 0.018706685 -2.57329588 0.923422564 -1.082927837 343 -4.50464524 0.00106759100 0.006313971 -1.031974008 0.923499943 -1.082837099 344 -4.136140891 0.00192196100 0.009605427 -1.639648926 0.923534378 -1.082796725 345 -3.091482075 0.01110326500 0.035177499 -3.428523652 0.923623551 -1.082692184 346 -3.936906064 0.00266092900 0.012188053 -1.974587934 0.923858036 -1.082417386 347 -5.350503047 0.00029759000 0.002579295 0.295154367 0.924131709 -1.082096837 348 -3.781820935 0.00343937900 0.014676164 -2.237974722 0.924139082 -1.082088205 349 -6.848194152 0.00003960000 0.000673517 2.396134025 0.92414144 -1.082085444 350 -6.471854762 0.00006390000 0.000919240 1.897709884 0.924454606 -1.081718879 351 -5.120964583 0.00041665800 0.003238646 -0.055093408 0.924464158 -1.081707702 352 -3.992024269 0.00243068300 0.011377126 -1.881520038 0.924653681 -1.081485988 353 -2.287328866 0.04462249800 0.099984429 -4.798481305 0.924766899 -1.081353584 354 -4.745750173 0.00073410000 0.004795176 -0.643651395 0.925014684 -1.081063919 355 -3.502877434 0.00549380500 0.020792455 -2.716459446 0.925014745 -1.081063848 356 -5.696914179 0.00018162800 0.001849178 0.809399196 0.925066785 -1.081003032 357 -3.235990306 0.00865942800 0.029201748 -3.178032026 0.925356395 -1.08066471 358 -5.236400527 0.00035145200 0.002884770 0.121989924 0.925377713 -1.080639815 359 -3.160153052 0.00986453300 0.032155286 -3.309487854 0.925486499 -1.080512791 360 -2.563478976 0.02771024400 0.069657481 -4.336632301 0.925823617 -1.080119346

[0502] Table 1.g3

[0503]

[0504]

[0505]

[0506] Table 1.g4

[0507]

[0508] Table 1.g5

[0509]

[0510] Table 1.g6

[0511]

[0512]

[0513] Table 2.a

[0514]

[0515] Table 2.b

[0516]

[0517]

[0518] Table 2.c

[0519]

[0520]

[0521] Table 2.d

[0522]

[0523] Table 2.e

[0524]

[0525]

[0526] Table 2.f

[0527]

[0528]

[0529] Table 2.g

[0530]

[0531]

[0532] Table 2.h

[0533]

[0534]

[0535] Table 2.i

[0536]

[0537] Table 2.j

[0538]

[0539]

[0540] Table 2.k

[0541] Gene Total probe count Significant probe count HyperG_Stats FDR_HyperG Significant percentage 1 IGF1R 104 16 0.007797893 0.171924974 15.38 2 CD6 56 14 0.000090300 0.005970563 25 3 CXCL13 108 14 0.046569042 0.598929617 12.96 4 IKBKB 46 12 0.000183630 0.010627608 26.09 5 PIK3R1 148 12 0.513477047 0.99999793 8.11 6 ITK 26 10 0.000015700 0.002607465 38.46 7 PTPRC 214 10 0.978491243 0.99999793 4.67 8 C8B 151 9 0.855915990 0.99999793 5.96 9 C8A 166 8 0.957766442 0.99999793 4.82 10 CCL18 42 8 0.016095432 0.256971894 19.05 11 CYFIP2 40 8 0.012066038 0.223463015 20 12 FAS 50 8 0.041957105 0.555032562 16 13 ICOSLG 40 8 0.012066038 0.223463015 20 14 IRF1 42 8 0.016095432 0.256971894 19.05 15 ITGAM 50 8 0.041957105 0.555032562 16 16 ITGAX 41 8 0.013975308 0.239650655 19.51 17 CCL3 33 7 0.013410837 0.238816059 21.21 18 CCL4 32 7 0.011323325 0.223463015 21.88 19 CD14 62 6 0.369692981 0.99999793 9.68 20 CD4 42 6 0.112492545 0.789152247 14.29 21 NFKB1 64 6 0.398773743 0.99999793 9.38 22 SYK 78 6 0.592795697 0.99999793 7.69 23 LAG3 29 5 0.075553312 0.710624303 17.24 24 AKT1 60 4 0.711822793 0.99999793 6.67 25 BLNK 66 4 0.779227696 0.99999793 6.06 26 C5 41 4 0.412035429 0.99999793 9.76 27 CASP8 41 4 0.412035429 0.99999793 9.76 28 CCR6 46 4 0.501622356 0.99999793 8.7 29 CD180 38 4 0.356577228 0.99999793 10.53 30 CD19 56 4 0.659150649 0.99999793 7.14

[0542] Table 3.a

[0543]

[0544]

[0545] Table 3.b

[0546] Gene Total probe count Significant probe count HyperG_Stats FDR_HyperG Significant percentage 63 HAVCR2 10 2 0.185613716 0.954389149 20 64 HLA-DMA 16 2 0.366542591 0.99999793 12.5 65 HLA-DMB 26 2 0.622797749 0.99999793 7.69 66 ICAM1 63 2 0.965115210 0.99999793 3.17 67 IFNG 10 2 0.185613716 0.954389149 20 68 IL25 74 2 0.983929844 0.99999793 2.7 69 IL26 20 2 0.479107134 0.99999793 10 70 IL3 42 2 0.857080857 0.99999793 4.76 71 IRF2 38 2 0.815788109 0.99999793 5.26 72 IRF3 30 2 0.700318757 0.99999793 6.67 73 IRF4 40 2 0.837619347 0.99999793 5 74 LTBR 33 2 0.749379647 0.99999793 6.06 75 LYN 48 2 0.903339407 0.99999793 4.17 76 PDCD1 36 2 0.791365183 0.99999793 5.56 77 PVR 65 2 0.969655536 0.99999793 3.08 78 RAC1 64 2 0.967461559 0.99999793 3.12 79 RAG1 51 2 0.920824528 0.99999793 3.92 80 RELA 56 2 0.943513220 0.99999793 3.57 81 SMAD3 34 2 0.764125503 0.99999793 5.88 82 STAT4 58 2 0.950729209 0.99999793 3.45 83 TNFRSF1A 46 2 0.889742685 0.99999793 4.35 84 TRAF2 46 2 0.889742685 0.99999793 4.35 85 TRAF6 60 2 0.957059624 0.99999793 3.33 86 UBC 64 2 0.967461559 0.99999793 3.12 87 CCL14 9 1 0.525100723 0.99999793 11.11 88 CCL16 9 1 0.525100723 0.99999793 11.11 89 ICAM2 24 1 0.862829697 0.99999793 4.17 90 ICAM4 53 1 0.987603129 0.99999793 1.89 91 IL12RB1 51 1 0.985366094 0.99999793 1.96 92 MCAM 33 1 0.934919833 0.99999793 3.03 93 PYCARD 6 1 0.391279132 0.99999793 16.67 94 SPA17 17 1 0.755090130 0.99999793 5.88

[0547] Table 3.c

[0548] Probe Locus Total probe count STAT5A_STAT5B_17_40403935_40406459_40464294_40468456_FR STAT5A-STAT5B 20 IRF1_5_131808352_131813604_131831068_131832754_FF IRF1 19 ITK_5_156605330_156608059_156693735_156698772_FR ITK 63 CD14_5_140023383_140027012_140050153_140052313_RF CD14 22 PDCD1LG2_9_5495992_5498009_5563479_5572986_RR CD274-PDCD1LG2 8

[0549] Table 4.a

[0550] HyperG_Stats FDR_HyperG Significant percentage logFC AveExpr 0.001866853 0.066190912 60 0.847262651666667 0.847262651666666 0.000987668 0.046843683 63.16 0.575333619 0.575333619 0.653537516 1 25.4 0.929375192333334 0.929375192333333 0.218923992 0.865271017 36.36 0.720976047333333 0.720976047333333 0.918612302 1 12.5 -0.351310575666667 -0.351310575666667

[0551] Table 4.b

[0552] t P-value adj.P. value B 7.35944594338825 0.000150927923435752 0.0102743339719173 1.64393419184962 5.64430691077999 0.000700956470870541 0.0155534374671815 -0.0160747735782962 8.2961135309084 0.0000610123228131512 0.00959185677856724 2.42787963605984 7.76177819268656 0.0000944498918420986 0.0097813496834544 2.00179581849286 -6.21225357321395 0.000390149640704813 0.0122622958225811 0.582455106574847

[0553] Table 4.c

[0554] FC FC_1 LS Detection ring 1.79931599399832 1.79931599399832 1 R 1.49002198650363 1.49002198650363 1 R 1.90445103081467 1.90445103081467 1 R 1.64829680346345 1.64829680346345 1 R 0.783871688209362 -1.27571899207682 -1 NR

[0555] Table 4.d

[0556] Probe sequence Probe location 60mer chromosome TTCCATAGATTACTTTTCAAATCATCCTTCGAAGCTGGCGGCTGAGGGCCCGGCGCCAAG 17 GTGTCTCGGCCCCCTGGGGCCCCACCCTTCGATTTCCCTGTTGCCGCCGCGTTTGCAAGA 5 ATCCCAACAAAAGAGAAGAACTTCTCCCTCGATGTTTGGGGGCGGAGGGCTTTGATGAGA 5 GTGGCGATGGCGGCCTGCGCGCCGCGCCTCGATGTCTAAGCAACCTGCTAACTGAGGCAG 5 ACAGTTATTAGAAAAATAAAACATTTGGTCGAACAGCAAAGAGAAGATATTCAACTGCGA 9

[0557] Table 4.e

[0558]

[0559] Table 4.f

[0560] 4kb sequence position End 2 40468295 131832752 156697736 140052311 5567480

[0561] Table 4.g

[0562] Internal primer Probe PCR-Primer1_ID STAT5A_STAT5B_17_40403935_40406459_40464294_40468456_FR OBD117-009 IRF1_5_131808352_131813604_131831068_131832754_FF OBD117-045 ITK_5_156605330_156608059_156693735_156698772_FR OBD117-089 CD14_5_140023383_140027012_140050153_140052313_RF OBD117-105 PDCD1LG2_9_5495992_5498009_5563479_5572986_RR OBD117-029

[0563] Table 4.h

[0564]

[0565] Table 4.i

[0566] Gene Markers GLMNET STAT5A-STAT5B OBD117-009 / 011 0.1947148 IRF1 OBD117-045 / 047 0.1946348 ITK OBD117-089 / 090 0.1938877 CD14 OBD117-105 / 107 0.193081 CD274-PDCD1LG2 OBD117-029 / 030 -0.1922868

[0567] Table 4.j

[0568]

[0569]

[0570]

[0571]

[0572]

[0573]

[0574]

[0575]

[0576] Stimulatory checkpoint molecules Inhibitory checkpoint molecules CD27 A2AR CD28 B7-H3 CD40 B7-H4 CD122 CTLA-4 CD137 IDO OX40 KIR GITR LAG3 ICOS PD-1 TIM-3 VISTA

[0577] Table 8

[0578]

[0579]

[0580] Table 9

[0581] drug target Preferred diseases Ipilimumab and nivolumab PD-1 and CTLA-4 Metastatic melanoma Paclitaxel, ipilimumab, and carboplatin CTLA4 Non-small cell lung cancer Ipilimumab and GVAX CTLA-4 Pancreatic cancer Pidizumab and rituximab PD-1 Hematologic malignancies L19-IL2 and L19-TNF STAT Melanoma MEDI0680 and durvalumab PD1 / PDL1 Advanced solid malignancies

[0582] Table 10. Combinations in cancer immunotherapy (biological agents, immune cytokines (L19-IL2 and L19-TNF), cytotoxins (paclitaxel)

[0583]

[0584]

[0585] Table 11. Other single molecules, immunocytokines, and biologics for cancer therapy

[0586]

[0587]

[0588]

[0589]

[0590]

[0591]

[0592]

[0593]

[0594]

[0595] Table 12

[0596]

[0597]

[0598] Table 13.a1

[0599] HyperG_Stats FDR_HyperG Significant percentage logFC AveExpr t 1 0.711822793 0.99999793 6.67 -0.219972658 -0.219972658 -4.996552469 2 0.18964104 0.954389149 11.43 -0.139786492 -0.139786492 -5.923845607 3 0.925958703 0.99999793 3.85 -0.15962933 -0.15962933 -6.204852631 4 0.073465475 0.710624303 14.29 -0.166543413 -0.166543413 -6.557217188 5 0.857080857 0.99999793 4.76 -0.1760267 -0.1760267 -8.001384234 6 0.001969408 0.075986326 22.73 -0.362483584 -0.362483584 -10.9324899 7 0.957766442 0.99999793 4.82 -0.374033997 -0.374033997 -10.68867959 8 0.229343441 1 25 0.338570638 0.338570638 3.416892289 9 0.85591599 0.99999793 5.96 -0.161358241 -0.161358241 -2.947668664 10 0.663352621 0.99999793 7.14 -0.339412631 -0.339412631 -13.55417084 11 0.889742685 0.99999793 4.35 -0.137531489 -0.137531489 -6.968042831 12 0.034964245 0.465381017 40 0.464289848 0.464289848 8.34149661 13 0.369692981 0.99999793 9.68 -0.178209877 -0.178209877 -7.696109127 14 0.764125503 0.99999793 5.88 -0.18498091 -0.18498091 -9.04469975 15 0.112492545 0.789152247 14.29 -0.139921516 -0.139921516 -5.076520451 16 9.03E-05 0.005970563 25 -0.21998431 -0.21998431 -6.891261434 17 9.03E-05 0.005970563 25 -0.149724624 -0.149724624 -8.117825922 18 9.03E-05 0.005970563 25 -0.159211463 -0.159211463 -8.406010145 19 9.03E-05 0.005970563 25 -0.321565937 -0.321565937 -13.11065547 20 9.03E-05 0.005970563 25 -0.207569599 -0.207569599 -8.105335573 21 9.03E-05 0.005970563 25 -0.169304269 -0.169304269 -9.223976152 22 0.203083688 0.988148592 12 -0.145793053 -0.145793053 -5.45369143 23 0.203083688 0.988148592 12 -0.348220668 -0.348220668 -12.64682486 24 0.203083688 0.988148592 12 -0.162924558 -0.162924558 -4.377302648 25 0.06993762 0.594154735 100 -0.191997367 -0.191997367 -3.324047424 26 0.999992975 0.99999793 1.73 -0.249667458 -0.249667458 -9.588148198 27 0.903339407 0.99999793 4.17 -0.144833276 -0.144833276 -7.422808069 28 0.13498553 0.877871412 50 -0.18736422 -0.18736422 -3.275422717 29 0.041957105 0.555032562 16 -0.193599779 -0.193599779 -5.573764843 30 0.041957105 0.555032562 16 -0.194159165 -0.194159165 -8.590649368 31 0.066362764 0.687693257 100 0.187306985 0.187306985 3.719020117 32 0.178427395 0.954389149 14.29 -0.211239457 -0.211239457 -3.939059704 33 0.012066038 0.223463015 20 -0.156295949 -0.156295949 -6.247769863 34 0.007797893 0.171924974 15.38 -0.178097117 -0.178097117 -7.086728608 35 0.037675475 0.528598335 18.75 -0.180180699 -0.180180699 -8.22189382 36 0.00018363 0.010627608 26.09 -0.304258892 -0.304258892 -11.89187759 37 0.00018363 0.010627608 26.09 -0.265642352 -0.265642352 -11.56467535 38 0.00018363 0.010627608 26.09 -0.325741973 -0.325741973 -15.03154881 39 0.00018363 0.010627608 26.09 -0.307578042 -0.307578042 -13.22491838 40 0.00018363 0.010627608 26.09 -0.393553534 -0.393553534 -17.46788221 41 0.00018363 0.010627608 26.09 -0.363126662 -0.363126662 -16.40706083 42 0.122126697 0.904598768 50 0.19255788 0.19255788 6.703121045 43 0.195485486 0.98238612 33.33 -0.261366196 -0.261366196 -5.18175145 44 0.016095432 0.256971894 19.05 -0.25495765 -0.25495765 -13.36737718 45 0.016095432 0.256971894 19.05 -0.147678268 -0.147678268 -6.626064358 46 0.016095432 0.256971894 19.05 -0.165001138 -0.165001138 -9.029584345 47 0.815788109 0.99999793 5.26 -0.204963087 -0.204963087 -3.763496869 48 0.700318757 0.99999793 6.67 -0.175351435 -0.175351435 -7.320634642 49 0.041957105 0.555032562 16 -0.266411523 -0.266411523 -9.608582862 50 0.041957105 0.555032562 16 -0.179650611 -0.179650611 -8.796652754 51 0.041957105 0.555032562 16 -0.215030115 -0.215030115 -9.152973735 52 0.013975308 0.239650655 19.51 -0.212953478 -0.212953478 -9.692570589

[0600] Table 13.a2

[0601]

[0602]

[0603] Table 13.a3

[0604]

[0605]

[0606]

[0607] Table 13.a4

[0608]

[0609]

[0610] Table 13.a5

[0611]

[0612]

[0613] Table 13.a6

[0614]

[0615]

[0616] Table 13.a7

[0617]

[0618]

[0619] Table 13.b1

[0620]

[0621]

[0622] Table 13.b2

[0623] P-value adj.P. value B FC FC_1 LS 53 0.0000109 0.000300885 3.734715272 0.885546684 -1.129245942 -1 54 0.00000334 0.000153695 4.950834477 0.867767745 -1.152382081 -1 55 0.000026 0.000519842 2.830950394 0.854495789 -1.170280782 -1 56 0.00000508 0.000194036 4.520831371 0.904407203 -1.105696634 -1 57 0.0000344 0.000618186 2.541955486 0.87572481 -1.141911236 -1 58 0.00000324 0.000150461 4.982857006 0.848279245 -1.178857087 -1 59 0.0000141 0.000355136 3.469495184 0.865409512 -1.155522312 -1 60 0.02197855 0.058573399 -4.108873892 0.866637776 -1.153884619 -1 61 0.00000643 0.000223311 4.277331934 0.867714714 -1.15245251 -1 62 0.00000998 0.000286168 3.824002229 0.878673343 -1.138079365 -1 63 0.0000607 0.0008901 1.95067007 0.907492164 -1.10193789 -1 64 0.00000209 0.000119285 5.430299258 0.873000772 -1.14547436 -1 65 0.0000000324 0.0000158 9.557329978 0.815875189 -1.225677668 -1 66 0.0000512 0.000797045 2.127853229 1.217620117 1.217620117 1 67 0.000000583 0.0000632 6.724276277 0.816806693 -1.224279879 -1 68 0.000000774 0.0000716 6.437875016 0.845326394 -1.18297501 -1 69 0.0000316 0.000584325 2.630230616 0.905061993 -1.104896689 -1 70 0.0000000092 0.0000107 10.73453386 0.777940153 -1.285445926 -1 71 0.00000165 0.000106067 5.674210448 0.884548664 -1.13052005 -1 72 0.00000113 0.0000855 6.052012506 0.814734156 -1.227394227 -1 73 0.0000000154 0.0000115 10.25824114 1.517878795 1.517878795 1 74 0.0000272 0.00053455 2.786912756 0.878524937 -1.138271616 -1 75 0.0000197 0.000439652 3.120890546 1.221831748 1.221831748 1 76 0.000000796 0.0000726 6.410227046 1.136563537 1.136563537 1 77 0.0000423 0.00070501 2.327593259 1.122774193 1.122774193 1 78 0.00020132 0.001977662 0.70216959 1.107609748 1.107609748 1 79 0.00000164 0.000106067 5.678158075 0.833487622 -1.199777866 -1 80 0.00000205 0.000117891 5.451255469 0.84378323 -1.18513851 -1 81 0.0000096 0.000278481 3.864510034 0.905023296 -1.104943933 -1 82 0.0000105 0.000294144 3.776112142 1.235187935 1.235187935 1 83 0.00000969 0.000280237 3.855144299 1.366483661 1.366483661 1 84 0.0000108 0.000298984 3.743323414 0.885454973 -1.129362905 -1 85 0.0000282 0.00054663 2.746937043 1.263536036 1.263536036 1 86 0.0000215 0.000464107 3.031396559 1.230769711 1.230769711 1 87 0.000000454 0.0000563 6.975413589 1.297798713 1.297798713 1 88 0.00000662 0.000226164 4.248389692 1.255372694 1.255372694 1 89 0.00000305 0.000145428 5.043130801 1.343762761 1.343762761 1 90 0.0000000294 0.0000153 9.64902897 1.223264684 1.223264684 1 91 0.000290264 0.002534245 0.32110467 0.896874612 -1.114983061 -1 92 0.0000335 0.000609191 2.568001061 0.897982647 -1.113607265 -1 93 0.0000623 0.000903821 1.924342502 0.891730663 -1.121414842 -1 94 0.010931496 0.034736273 -3.41285233 1.280848257 1.280848257 1 95 0.013665308 0.041030377 -3.636678978 1.274996095 1.274996095 1 96 0.00000301 0.000144884 5.057553149 1.242796139 1.242796139 1 97 0.008183105 0.027939057 -3.120846211 0.797862089 -1.253349437 -1 98 0.012168576 0.037672866 -3.520502123 0.879662072 -1.136800178 -1 99 0.014916282 0.043846027 -3.724182352 0.907057882 -1.102465476 -1 100 0.009318298 0.030820985 -3.252058133 0.80221645 -1.246546365 -1 101 0.004239872 0.0171443 -2.452133159 0.761934695 -1.312448438 -1 102 0.012799247 0.039057427 -3.571146947 0.862654151 -1.159213108 -1 103 0.002310795 0.010964378 -1.829468152 0.90372659 -1.106529354 -1 104 0.000185463 0.001878108 0.787632865 0.857293116 -1.166462184 -1

[0624] Table 13.b3

[0625]

[0626]

[0627] Table 13.b4

[0628]

[0629]

[0630] Table 13.b5

[0631]

[0632]

[0633] Table 13.b6

[0634]

[0635]

[0636] Table 13.b7

[0637]

[0638]

[0639] Table 13.c1

[0640]

[0641]

[0642] Table 13.c2

[0643]

[0644]

[0645] Table 13.c3

[0646]

[0647]

[0648] Table 13.c4

[0649]

[0650] Table 13.c5

[0651]

[0652]

[0653] Table 13.c6

[0654]

[0655]

[0656] Table 13.c7

[0657]

[0658]

[0659] Table 13.d1

[0660]

[0661]

[0662] Table 13.d2

[0663]

[0664]

[0665] Table 13.d3

[0666]

[0667]

[0668]

[0669] Table 13.d4

[0670]

[0671] Table 13.d5

[0672]

[0673] Table 13.d6

[0674]

[0675]

[0676] Table 13.d7

[0677]

[0678]

[0679] Table 13.e1

[0680]

[0681]

[0682] Table 13.e2

[0683]

[0684]

[0685] Table 13.e3

[0686]

[0687]

[0688]

[0689] Table 13.e4

[0690]

[0691]

[0692] Table 13.e5

[0693]

[0694] Table 13.e6

[0695]

[0696] Table 13.e7

[0697]

[0698]

[0699] Table 13.f1

[0700]

[0701]

[0702] Table 13.f2

[0703]

[0704]

[0705] Table 13.f3

[0706]

[0707]

[0708]

[0709] Table 13.f4

[0710]

[0711]

[0712] Table 13.f5

[0713]

[0714]

[0715] Table 13.f6

[0716]

[0717]

[0718] Table 13.f7

[0719] Probe Locus Total probe count Significant probe count 313 ORF541_7_77589308_77593066_77652906_77658625_RF ORF541 23 4 314 ORF541_7_77628734_77632614_77645983_77651804_FF ORF541 23 4 315 ORF544_1_198591683_198595771_198768850_198775826_FF PTPRC 214 10 316 ORF544_1_198659753_198666156_198697386_198704777_FR ORF544 187 30 317 ORF544_1_198659753_198666156_198735456_198749256_FF ORF544 187 30 318 ORF544_1_198735456_198749256_198779053_198786841_RF ORF544 187 30 319 ORF547_11_82936602_82938148_83048972_83059269_RR ORF547 99 7 320 ORF547_11_82938763_82948488_82974616_82981008_FR ORF547 99 7 321 ORF55_11_64267793_64269811_64288581_64290103_FR BAD 70 8 322 ORF55_11_64267793_64269811_64292591_64296924_FF BAD 70 8 323 ORF552_1_174835362_174838725_175007460_175017921_RF ORF552 93 6 324 ORF553_7_6325447_6327369_6392091_6396545_RR RAC1 64 2 325 ORF554_20_20425025_20439432_20458256_20459854_RF ORF554 117 8 326 ORF556_13_97440604_97443754_97479189_97487608_FF ORF556 66 5 327 ORF558_2_33390711_33398991_33442363_33444238_FR ORF558 34 5 328 ORF56_14_75477136_75478350_75491596_75496634_FR ORF56 18 2 329 ORF56_14_75491596_75496634_75573735_75577816_RF ORF56 18 2 330 ORF560_21_14176916_14181369_14267912_14269012_RF ORF560 37 3 331 ORF560_21_14210379_14215717_14236469_14248873_RR ORF560 37 3 332 ORF564_21_34500925_34506011_34574861_34579728_FR ORF564 67 7 333 ORF567_11_65634932_65641044_65653258_65654626_RF RELA 56 2 334 ORF568_12_18259444_18261081_18350532_18364514_FF ORF568 34 5 335 ORF569_3_16448043_16456162_16496760_16499694_FF ORF569 139 10 336 ORF57_19_48914276_48916713_48932242_48935310_FF ORF57 30 6 337 ORF57_19_48914276_48916713_48968306_48971572_FF ORF57 30 6 338 ORF576_6_3027907_3030237_3146778_3149848_FR ORF576 25 8 339 ORF576_6_3045545_3051391_3146778_3149848_FR ORF576 25 8 340 ORF576_6_3114019_3116008_3146778_3149848_RR ORF576 25 8 341 ORF586_6_166614982_166618999_166826698_166835940_RR ORF586 176 12 342 ORF586_6_166614982_166618999_166877620_166884513_RR ORF586 176 12 343 ORF589_21_35511164_35517830_35766255_35775694_FF ORF589 197 5 344 ORF59_20_50749321_50753502_50888426_50893318_FR ORF59 17 4 345 ORF596_1_243286011_243289794_243392615_243398557_RF ORF596 151 9 346 ORF596_1_243386248_243390518_243516824_243527512_RF ORF596 151 9 347 ORF603_18_44885635_44895879_44997556_45002564_FR ORF603 156 11 348 ORF603_18_44885635_44895879_45014599_45017752_FR ORF603 156 11 349 ORF605_1_66506442_66514114_66751280_66753550_RF ORF605 163 8 350 ORF605_1_66578981_66592963_66761002_66762820_RF ORF605 163 7 351 ORF611_20_1857555_1861228_1955166_1964657_FR ORF611 59 7 352 ORF611_20_1891489_1897350_1924633_1930962_RR SIRPA 56 4 353 ORF613_1_160707882_160714935_160743813_160744937_RF ORF613 27 1 354 ORF618_6_3272293_3273348_3492046_3503752_FF ORF618 158 8 355 ORF624_2_27626184_27635183_27719544_27726504_RF ORF624 24 2 356 ORF626_5_150149497_150151091_150181302_150194775_FR ORF626 34 5 357 ORF626_5_150162904_150166548_150181302_150194775_FR ORF626 34 5 358 ORF626_5_150162904_150166548_150194890_150198993_FR ORF626 34 0 359 ORF626_5_150181302_150194775_150230115_150237336_RF ORF626 34 5 360 ORF626_5_150181302_150194775_150237336_150238718_RF ORF626 34 5 361 ORF630_17_35287155_35289074_35307929_35312497_FF ORF630 18 3 362 ORF631_15_67098632_67101498_67199584_67204251_RR SMAD3 34 2 363 ORF642_16_29613904_29616227_29630194_29632081_RF SPN 56 4 364 ORF642_16_29613904_29616227_29686079_29687229_RF SPN 56 4

[0720] Table 13.g1

[0721] HyperG_Stats FDR_HyperG Significant percentage logFC AveExpr t 313 0.053424912 0.606428812 17.39 0.356643448 0.356643448 3.960789133 314 0.053424912 0.606428812 17.39 0.285214138 0.285214138 4.609256093 315 0.978491243 0.99999793 4.67 -0.14040288 -0.14040288 -5.186348648 316 2.30E-06 0.000217011 16.04 0.283822723 0.283822723 11.36017484 317 2.30E-06 0.000217011 16.04 0.28622671 0.28622671 10.23998629 318 2.30E-06 0.000217011 16.04 0.312760316 0.312760316 7.112432884 319 0.433763829 1 7.07 0.377286081 0.377286081 4.904828931 320 0.433763829 1 7.07 0.319635014 0.319635014 4.836776666 321 0.18964104 0.954389149 11.43 -0.146341453 -0.146341453 -5.009008006 322 0.18964104 0.954389149 11.43 -0.155897691 -0.155897691 -6.419907226 323 0.587989675 1 6.45 0.162077594 0.162077594 6.758085183 324 0.967461559 0.99999793 3.12 -0.432758998 -0.432758998 -5.571884831 325 0.459116235 1 6.84 0.446838664 0.446838664 12.24134889 326 0.403635377 1 7.58 0.423159851 0.423159851 10.02547665 327 0.06020741 0.646636236 14.71 0.297744446 0.297744446 8.756884365 328 0.337741302 1 11.11 0.196386472 0.196386472 6.01640946 329 0.337741302 1 11.11 0.168913942 0.168913942 6.493464138 330 0.415513464 1 8.11 0.309983092 0.309983092 11.42911374 331 0.415513464 1 8.11 0.355272886 0.355272886 9.89272102 332 0.12838934 0.904598768 10.45 0.289530526 0.289530526 10.39257872 333 0.94351322 0.99999793 3.57 -0.335793252 -0.335793252 -14.59846809 334 0.06020741 0.646636236 14.71 0.301770409 0.301770409 9.8018573 335 0.380387396 1 7.19 0.306584347 0.306584347 2.955558359 336 0.01000538 0.181608098 20 0.319528065 0.319528065 12.82607629 337 0.01000538 0.181608098 20 0.294074256 0.294074256 15.40919841 338 0.000101223 0.003977202 32 0.342315512 0.342315512 4.823515277 339 0.000101223 0.003977202 32 0.381150282 0.381150282 7.660425289 340 0.000101223 0.003977202 32 0.471818762 0.471818762 6.947243306 341 0.432643309 1 6.82 0.334089996 0.334089996 5.008617015 342 0.432643309 1 6.82 0.378448027 0.378448027 6.858042974 343 0.995427013 1 2.54 0.309719719 0.309719719 3.570772465 344 0.019351438 0.304140094 23.53 0.310572354 0.310572354 7.361954056 345 0.617155598 1 5.96 0.388082401 0.388082401 11.1208405 346 0.617155598 1 5.96 0.295082217 0.295082217 6.643633956 347 0.395653632 1 7.05 0.2983925 0.2983925 6.884745917 348 0.395653632 1 7.05 0.286095812 0.286095812 5.99074538 349 0.854051613 1 4.91 0.249385621 0.249385621 2.70486202 350 0.894561341 1 4.29 0.302395192 0.302395192 6.269378105 351 0.076789008 0.731434696 11.86 0.347062258 0.347062258 6.676297968 352 0.659150649 0.99999793 7.14 -0.183746617 -0.183746617 -7.539838325 353 0.858892218 1 3.7 -0.306060504 -0.306060504 -4.552793946 354 0.785606032 1 5.06 0.307291844 0.307291844 7.043291289 355 0.479347944 1 8.33 0.148041193 0.148041193 4.147781826 356 0.085664563 0.667617217 14.71 -0.191241299 -0.191241299 -9.324329472 357 0.085664563 0.667617217 14.71 -0.213609391 -0.213609391 -10.1665293 358 1 1 0 -0.157170259 -0.157170259 -6.502829914 359 0.085664563 0.667617217 14.71 -0.193972875 -0.193972875 -11.86119945 360 0.085664563 0.667617217 14.71 -0.152338864 -0.152338864 -9.193910673 361 0.100654026 0.825363011 16.67 0.309628617 0.309628617 5.989078991 362 0.764125503 0.99999793 5.88 -0.180175335 -0.180175335 -8.471609217 363 0.659150649 0.99999793 7.14 -0.175972335 -0.175972335 -7.054965999 364 0.659150649 0.99999793 7.14 -0.16436617 -0.16436617 -7.773176867

[0722] Table 13.g2

[0723]

[0724]

[0725] Table 13.g3

[0726]

[0727]

[0728]

[0729] Table 13.g4

[0730]

[0731]

[0732] Table 13.g5

[0733]

[0734]

[0735] Table 13.g6

[0736]

[0737]

[0738] Table 13.g7

[0739]

[0740]

[0741] Table 13.h1

[0742]

[0743]

[0744] Table 13.h2

[0745] P-value adj.P. value B FC FC_1 LS 365 0.0000783 0.001057554 1.685518605 0.869060387 -1.150668026 -1 366 0.000187328 0.001890561 0.777210943 0.898177691 -1.11336544 -1 367 0.0135104 0.040653116 -3.625275836 1.43309024 1.43309024 1 368 0.018664657 0.051850278 -3.94720067 1.534363795 1.534363795 1 369 0.0000832 0.001097922 1.622590571 1.218333322 1.218333322 1 370 0.00000689 0.000230944 4.20728549 1.223046441 1.223046441 1 371 0.0000123 0.000322648 3.609042444 1.237393443 1.237393443 1 372 0.002489795 0.011583149 -1.906237636 1.256859701 1.256859701 1 373 0.002248311 0.010748006 -1.801247822 1.231240479 1.231240479 1 374 0.0000249 0.000505697 2.876053795 1.225289553 1.225289553 1 375 0.000241882 0.002233638 0.510978947 1.223098996 1.223098996 1 376 0.0000807 0.001076073 1.654796525 0.89941508 -1.111833704 -1 377 0.000000369 0.000051 7.182375543 1.17230248 1.17230248 1 378 0.000000162 0.0000357 7.999309139 1.183250597 1.183250597 1 379 0.00000111 0.0000849 6.073270515 1.131175803 1.131175803 1 380 0.00000172 0.000108368 5.628079247 0.883077855 -1.132402986 -1 381 0.000000147 0.0000335 8.09397041 0.859734296 -1.163150063 -1 382 0.0017087 0.008848343 -1.518311904 0.844926717 -1.183534596 -1 383 0.000717954 0.004728245 -0.62056802 0.851025509 -1.175052908 -1 384 0.0000198 0.000441092 3.114727283 0.896287748 -1.11571312 -1 385 0.001142097 0.006622538 -1.101830789 1.639151616 1.639151616 1 386 0.026579755 0.067536623 -4.295830899 0.783634368 -1.276105338 -1 387 0.00000506 0.000193388 4.525216296 1.237848888 1.237848888 1 388 0.000000611 0.0000645 6.675922138 0.849238289 -1.177525805 -1 389 0.0000475 0.000761747 2.207019697 0.873677956 -1.144586507 -1 390 0.000055 0.000832022 2.053813675 1.257279485 1.257279485 1 391 0.000138772 0.001546149 1.089794369 0.879878021 -1.136521172 -1 392 0.000025 0.000506888 2.872175551 0.894218465 -1.118294958 -1 393 0.00000000279 0.00000683 11.81480874 0.802787883 -1.245659061 -1 394 0.00000168 0.000107198 5.651749271 0.762306283 -1.311808681 -1 395 0.000000163 0.0000357 7.991924175 0.786188466 -1.271959642 -1 396 0.00000135 0.0000949 5.875116011 0.803281037 -1.24489432 -1 397 0.000000535 0.0000603 6.809806578 0.79840406 -1.252498641 -1 398 0.000399013 0.003153947 -0.010076757 0.874625168 -1.143346929 -1 399 0.000858885 0.005371224 -0.806528239 0.899529384 -1.111692423 -1 400 0.000000259 0.0000428 7.533224813 0.863339802 -1.158292479 -1 401 0.0000359 0.000632929 2.498799383 0.749563705 -1.33410942 -1 402 0.00000221 0.000123757 5.375272803 1.225332239 1.225332239 1 403 0.00000745 0.000241272 4.126320504 0.842010382 -1.187633812 -1 404 0.001037188 0.006177722 -1.00204781 1.120176602 1.120176602 1 405 0.0000451 0.000738802 2.260334671 1.149582943 1.149582943 1 406 0.0000548 0.000830816 2.057190334 0.872594655 -1.146007478 -1 407 0.001237916 0.007019121 -1.185214291 0.902084331 -1.108543809 -1 408 0.0000897 0.001156677 1.544601478 0.870989334 -1.148119685 -1 409 0.000000811 0.0000728 6.391477553 0.837740969 -1.193686398 -1 410 0.000000593 0.0000638 6.707137194 0.875972399 -1.141588481 -1 411 0.0000000638 0.0000214 8.907819219 1.513169114 1.513169114 1 412 0.001752953 0.009007702 -1.544700881 1.223058727 1.223058727 1 413 0.000000165 0.0000357 7.977910939 1.216617834 1.216617834 1 414 0.000000483 0.0000579 6.912800589 0.775013085 -1.290300795 -1 415 0.00000069 0.0000687 6.554375143 1.288748791 1.288748791 1 416 0.002129042 0.010339113 -1.745111267 1.284993527 1.284993527 1

[0746] Table 13.h3

[0747]

[0748]

[0749] Table 13.h4

[0750]

[0751]

[0752] Table 13.h5

[0753]

[0754]

[0755] Table 13.h6

[0756]

[0757]

[0758] Table 13.h7

[0759]

[0760]

[0761] Table 13.i1

[0762] HyperG_Stats FDR_HyperG Significant percentage logFC AveExpr t 417 0.001789508 0.045608266 24.14 0.168923652 0.168923652 4.273129747 418 0.002398244 0.056538599 24.14 0.144207368 0.144207368 6.014120556 419 0.002398244 0.056538599 24.14 0.199604737 0.199604737 8.688296791 420 0.002398244 0.056538599 24.14 0.1824608 0.1824608 7.192394868 421 0.002398244 0.056538599 24.14 0.172829165 0.172829165 5.388588036 422 0.002398244 0.056538599 24.14 0.173973685 0.173973685 6.172747925 423 0.994563707 1 1.77 0.295771685 0.295771685 3.019840274 424 0.000164355 0.005961019 14.2 0.340118684 0.340118684 13.02892826 425 0.000164355 0.005961019 14.2 0.313675221 0.313675221 5.453800736 426 0.000164355 0.005961019 14.2 0.308984949 0.308984949 13.67253532 427 0.000164355 0.005961019 14.2 0.370970871 0.370970871 8.877555847 428 0.000164355 0.005961019 14.2 0.293427802 0.293427802 8.432951342 429 0.000164355 0.005961019 14.2 0.30374268 0.30374268 7.655073619 430 0.000164355 0.005961019 14.2 0.355774756 0.355774756 5.513101893 431 0.999995464 0.99999793 1.1 -0.197007746 -0.197007746 -4.723247929 432 0.000164355 0.005961019 14.2 0.30240493 0.30240493 7.643472828 433 0.513477047 0.99999793 8.11 -0.331665721 -0.331665721 -11.91788456 434 0.513477047 0.99999793 8.11 -0.356573442 -0.356573442 -14.85687535 435 0.513477047 0.99999793 8.11 -0.31812964 -0.31812964 -14.30149147 436 0.7582782 0.99999793 6.25 -0.385982839 -0.385982839 -17.18527923 437 2.29E-06 0.000217011 34.38 0.321601025 0.321601025 10.73971674 438 2.29E-06 0.000217011 34.38 0.284709632 0.284709632 9.679151953 439 0.687444338 0.99999793 6.98 -0.140265969 -0.140265969 -6.28050969 440 0.687444338 0.99999793 6.98 -0.187583846 -0.187583846 -5.431560127 441 0.687444338 0.99999793 6.98 -0.139084539 -0.139084539 -6.11708923 442 0.062022042 0.70039526 16.67 -0.174771304 -0.174771304 -4.501723442 443 0.062022042 0.70039526 16.67 -0.140520637 -0.140520637 -6.954162178 444 0.659150649 0.99999793 7.14 -0.169924144 -0.169924144 -7.327193408 445 0.659150649 0.99999793 7.14 -0.153139995 -0.153139995 -6.667140097 446 0.001866853 0.066190912 60 0.870424687 0.870424687 6.817040924 447 0.050279839 0.592673603 33.33 0.289411908 0.289411908 8.185158835 448 0.050279839 0.592673603 33.33 0.421540272 0.421540272 12.7959067 449 0.366131493 1 14.29 0.295150757 0.295150757 5.356815514 450 0.251755367 1 25 -0.152450898 -0.152450898 -7.330250938 451 0.889742685 0.99999793 4.35 -0.200276865 -0.200276865 -7.487088438 452 6.44E-05 0.004967399 23.53 -0.330748028 -0.330748028 -18.17630665 453 6.44E-05 0.004967399 23.53 -0.375198131 -0.375198131 -11.77686613 454 6.44E-05 0.004967399 23.53 -0.342250575 -0.342250575 -12.06306132 455 6.44E-05 0.004967399 23.53 -0.358891419 -0.358891419 -10.66682351 456 6.44E-05 0.004967399 23.53 -0.282267049 -0.282267049 -15.53979703 457 0.177479538 1 33.33 0.138918287 0.138918287 7.319723967 458 0.112492545 0.789152247 14.29 -0.165440732 -0.165440732 -5.606610708 459 0.112492545 0.789152247 14.29 -0.22976066 -0.22976066 -9.762488772 460 0.889742685 0.99999793 4.35 -0.18670662 -0.18670662 -5.163579985

[0763] Table 13.i2

[0764] P-value adj.P. value B FC FC_1 LS 417 0.001541322 0.008215323 -1.41185712 1.124219428 1.124219428 1 418 0.000117273 0.001382765 1.265161339 1.10512332 1.10512332 1 419 0.00000481 0.000187071 4.576477583 1.148383683 1.148383683 1 420 0.0000259 0.000518564 2.835496877 1.134817891 1.134817891 1 421 0.000281632 0.002477042 0.352536792 1.127266921 1.127266921 1 422 0.0000947 0.001202019 1.487699995 1.128161559 1.128161559 1 423 0.01256505 0.038542086 -3.55264462 1.227541403 1.227541403 1 424 0.000000105 0.0000268 8.427168566 1.265860726 1.265860726 1 425 0.000256392 0.002326445 0.450307706 1.242869843 1.242869843 1 426 0.0000000654 0.0000214 8.883474649 1.238835774 1.238835774 1 427 0.00000395 0.00016934 4.778806192 1.293222821 1.293222821 1 428 0.00000631 0.000221388 4.297454598 1.225548689 1.225548689 1 429 0.000015 0.000371302 3.4022934 1.234342429 1.234342429 1 430 0.000235533 0.00219625 0.538683933 1.279672607 1.279672607 1 431 0.000759949 0.004919307 -0.679565911 0.872358022 -1.14631834 -1 432 0.0000152 0.000374316 3.388405516 1.233198406 1.233198406 1 433 0.000000248 0.0000426 7.579137577 0.794618496 -1.258465547 -1 434 0.000000029 0.0000153 9.663464141 0.78101738 -1.280381239 -1 435 0.0000000421 0.0000172 9.306864203 0.802109086 -1.246713219 -1 436 0.00000000688 0.0000106 11.00320387 0.765257487 -1.30674971 -1 437 0.000000669 0.0000679 6.585681171 1.249716647 1.249716647 1 438 0.00000178 0.000110226 5.595735187 1.218165062 1.218165062 1 439 0.0000821 0.001088928 1.636855792 0.907351864 -1.102108277 -1 440 0.000264717 0.002374878 0.417032009 0.878075047 -1.138854821 -1 441 0.00010205 0.001261051 1.410021654 0.908095203 -1.101206125 -1 442 0.001072501 0.006331857 -1.036726499 0.885907942 -1.128785456 -1 443 0.0000347 0.000620295 2.533051066 0.907191711 -1.102302841 -1 444 0.0000221 0.000471182 3.003395936 0.888889417 -1.124999331 -1 445 0.0000497 0.000781417 2.158738806 0.899291043 -1.111987056 -1 446 0.000217825 NA 1.17150928 1.82820099 1.82820099 1 447 0.00000826 0.000257888 4.019841765 1.222141989 1.222141989 1 448 0.000000125 0.0000307 8.255863058 1.339356736 1.339356736 1 449 0.000294879 0.00256113 0.304679742 1.22701319 1.22701319 1 450 0.000022 0.000469868 3.00717754 0.899720688 -1.111456047 -1 451 0.0000183 0.000418541 3.199585235 0.870383513 -1.148918821 -1 452 0.00000000394 0.00000864 11.50694716 0.79512411 -1.257665297 -1 453 0.000000277 0.0000445 7.465604014 0.770999521 -1.297017667 -1 454 0.00000022 0.0000394 7.6945755 0.788809824 -1.26773269 -1 455 0.000000713 0.0000695 6.520700487 0.779763527 -1.282440079 -1 456 0.0000000186 0.0000129 10.08124721 0.822297844 -1.216104368 -1 457 0.0000223 0.000473074 2.994152645 1.101079232 1.101079232 1 458 0.000206242 0.002008025 0.677010146 0.891656084 -1.121508638 -1 459 0.00000164 0.000106067 5.677124024 0.852776354 -1.172640394 -1 460 0.000391198 0.003113294 0.010501538 0.87860912 -1.138162554 -1

[0765] Table 13.i3

[0766]

[0767]

[0768]

[0769] Table 13.i4

[0770]

[0771] Table 13. i5

[0772]

[0773] Table 13. i6

[0774]

[0775]

[0776] Table 13.i7

[0777]

[0778]

[0779] Table 14.a

[0780]

[0781]

[0782] Table 14.b

[0783]

[0784]

[0785] Table 14.c

[0786] Gene Markers GLMNET ORF243 OBD117.1.717.719 -0.023642297 ORF243 OBD117.1.901.903 0.007197773 ORF243 OBD117.1.905.907 -0.014372166 ORF243 OBD117.1.573.575 -0.000142339 ORF243 OBD117.1.897.899 0.009781389 ORF249 OBD117.1.1317.1319 0 ORF249 OBD117.1.1529.1531 0 ORF25 OBD117.1.1445.1447 0 ORF25 OBD117.1.1165.1167 0 ORF252 OBD117.1.1201.1203 0 ORF257 OBD117.1.1401.1403 0 GAB2 OBD117.1.141.143 -0.007419107 ORF263 OBD117.1.1325.1327 0 ORF264 OBD117.1.1333.1335 0 ORF264 OBD117.1.1833.1835 0 ORF264 OBD117.1.1785.1787 0 ORF264 OBD117.1.1377.1379 0 ORF264 OBD117.1.1741.1743 0 ORF264 OBD117.1.1141.1143 0 ORF264 OBD117.1.1841.1843 0 ORF264 OBD117.1.1845.1847 0 ORF272 OBD117.1.1225.1227 0 ORF276 OBD117.1.1061.1063 0 ORF285 OBD117.1.923.925 0.000121346 ORF290 OBD117.1.1777.1779 0 ORF290 OBD117.1.1101.1103 0 HLA-DQA1 OBD117.1.401.403 0.009992562 HLA-DQA1 OBD117.1.721.723 0.00011425 HLA-DQA1 OBD117.1.413.415 0.002234049 HLA-DQA1 OBD117.1.425.427 0.0000993 ORF30 OBD117.1.1749.1751 0 IGF1R OBD117.1.209.211 0.012827643 IGF1R OBD117.1.317.319 -0.010330599 IGF1R OBD117.1.101.103 0.0000979 IKBKB OBD117.1.757.759 0.00012094 IKBKB OBD117.1.281.283 -0.00399849 IKBKB OBD117.1.037.039 0.002891486 IKBKB OBD117.1.073.075 0.017565968 ORF313 OBD117.1.693.695 -0.022219432 ORF313 OBD117.1.929.931 -0.015662127 ORF313 OBD117.1.665.667 0.000119444 ORF313 OBD117.1.581.583 -0.027382095 ORF316 OBD117.1.1041.1043 0 ORF316 OBD117.1.485.487 0 IL25 OBD117.1.289.291 0.007589853 ORF319 OBD117.1.1017.1019 0 ORF325 OBD117.1.881.883 0.000113252 ORF325 OBD117.1.1129.1131 0 ORF325 OBD117.1.653.655 0.003005705 IRF1 OBD117.1.765.767 -0.010031296 IRF3 OBD117.1.285.287 -0.025409945 ITGAX OBD117.1.177.179 0.006986068 ITGAX OBD117.1.173.175 0.004807037 ITK OBD117.1.165.167 -0.004038003

[0787] Table 14.d

[0788] Gene Markers GLMNET ORF344 OBD117.1.585.587 0.000108113 ORF344 OBD117.1.593.595 -0.012488304 ORF346 OBD117.1.1717.1719 0 ORF346 OBD117.1.1617.1919 0 ORF348 OBD117.1.1289.1291 0 ORF348 OBD117.1.1605.1607 0 ORF362 OBD117.1.1513.1515 0 ORF362 OBD117.1.1469.1471 0 ORF368 OBD117.1.1337.1339 0 ORF369 OBD117.1.925.927 0.015771071 ORF375 OBD117.1.1397.1399 0 ORF38 OBD117.1.1113.1115 0 ARHGEF7 OBD117.1.157.159 -0.008898153 ORF38 OBD117.1.1457.1459 0 ARHGEF7 OBD117.1.725.727 0.00011344 ORF380 OBD117.1.1849.1851 0 ORF380 OBD117.1.1829.1831 0 ORF382 OBD117.1.1421.1423 0 ORF385 OBD117.1.977.979 0 ORF385 OBD117.1.965.967 -0.006509693 ORF39 OBD117.1.1821.1823 0 ORF39 OBD117.1.1857.1859 0 ORF390 OBD117.1.1301.1303 0 ORF393 OBD117.1.1229.1231 0 ORF396 OBD117.1.477.479 0.011140328 ORF396 OBD117.1.553.555 0 ORF400 OBD117.1.1177.1179 0 MAPK10 OBD117.1.221.223 -0.009554407 MAPKAP1 OBD117.1.033.035 -0.010767501 ORF404 OBD117.1.1133.1135 0 ORF404 OBD117.1.1285.1287 0 ORF408 OBD117.1.1693.1695 0 ORF41 OBD117.1.1581.1583 0 ORF41 OBD117.1.1637.1639 0 ORF415 OBD117.1.1713.1715 0 ORF415 OBD117.1.1205.1207 0 ORF420 OBD117.1.1729.1731 0 ORF430 OBD117.1.1429.1431 0 ORF430 OBD117.1.1089.1091 0 ORF430 OBD117.1.1589.1591 0 ORF430 OBD117.1.1493.1495 0 ORF430 OBD117.1.1661.1663 0 ORF430 OBD117.1.1081.1083 0 ORF430 OBD117.1.1085.1087 0 ORF430 OBD117.1.1509.1511 0 ORF430 OBD117.1.1489.1491 0 ORF433 OBD117.1.1053.1055 0 ORF439 OBD117.1.1697.1699 0 ORF440 OBD117.1.1149.1151 0 ORF440 OBD117.1.1505.1507 0 PIK3R1 OBD117.1.829.831 0.000114527 ORF442 OBD117.1.1417.1419 0 ORF442 OBD117.1.1677.1679 0 ORF447 OBD117.1.1021.1023 0

[0789] Table 14.e

[0790]

[0791]

[0792] Table 14.f

[0793]

[0794]

[0795] Table 14.g

[0796]

[0797]

[0798] Table 14.h

[0799]

[0800]

[0801] Table 14.i

[0802]

[0803] Table 15

[0804]

[0805]

[0806] Table 16.a

[0807]

[0808]

[0809] Table 16.b

[0810]

[0811]

[0812] Table 16.c

[0813]

[0814]

[0815] Table 16.d

[0816]

[0817]

[0818] Table 16.e

[0819]

[0820]

[0821] Table 17.a

[0822]

[0823]

[0824] Table 17.b

[0825] Gene Marker GLMNET IL17RA OBD115-385.387 -0.099598169 TP53 OBD115-397.399 -0.089892616 IL4 OBD115-425.427 -0.095230215 EFNB1 OBD115-477.479 0.091808032 IFNA2 OBD117-109.111 -0.130270706 BBC3 OBD117-085.087 -0.076629581 KLRK1 OBD117-053.055 -0.088944337 IFNA1 OBD117-033.035 0.111911072 PIK3CA OBD117-117.119 -0.039841311 BIRC2 OBD117-101.103 -0.116970742 PDCD1 OBD117-057.059 0.13271562 XIAP OBD117-073.075 0.036539075 BCL2 OBD115-429.431 0 CD6 OBD115-281.283 0.031298493 CDKN2A OBD115-277.279 0 FAS OBD115-293.295 0.035034651 PTPRA OBD115-165.103 -0.042684846

[0826] Table 18.

Claims

1. Use of at least 5 probe sequences in the preparation of a reagent for determining the responsiveness of an individual to an anti-PD-L1 therapy for lung cancer, the determination comprising detecting the presence or absence of at least 5 chromosome interactions corresponding to the at least 5 probe sequences in a sample from the individual, wherein: The detection includes: (i) cross-linking chromosome interactions present in the sample to prepare cross-linked DNA, (ii) subjecting the cross-linked DNA to shearing, (iii) ligating the cross-linked sheared DNA ends to prepare ligated DNA, and (iv) identifying the presence or absence of said linked DNA to which said at least five probe sequences bind, thereby identifying the presence or absence of said at least five chromosomal interactions; and Wherein, the 5 probe sequences are: TTCCATAGATTACTTTTCAAATCATCCTTCGAAGCTGGCGGCTGAGGGCCCGGCGCCAAG, GTGTCTCGGCCCCCTGGGGCCCCACCCTTCGATTTCCCTGTTGCCGCCGCGTTTGCAAGA, ATCCCAACAAAAGAGAAGAACTTCTCCCTCGATGTTTGGGGGCGGAGGGCTTTGATGAGA, GTGGCGATGGCGGCCTGCGCGCCGCGCCTCGATGTCTAAGCAACCTGCTAACTGAGGCAG, and ACAGTTATTAGAAAAATAAAACATTTGGTCGAACAGCAAAGAGAAGATATTCAACTGCGA.

2. The use according to claim 1, wherein: Detecting the presence or absence of the chromosomal interaction comprises specifically detecting the linked DNA by quantitative PCR, the quantitative PCR also using primers capable of amplifying the linked DNA, and wherein the at least 5 probes comprise: a fluorophore covalently linked to the 5' end of the probe, or A quencher is covalently attached to the 3' end of the probe.

3. The use according to claim 2, wherein: The fluorophore is selected from the group consisting of HEX, Texas Red and FAM.